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Abstract 
 
Information on the molecular details of human skin wound healing has been limited 
due to several types of challenges faced when data from basic research are adapted for 
use in clinical studies. Comprehensive genomewide data on gene behaviour during 
the various phases of wound healing have not been available, although many 
techniques, such as gene expression microarrays and RNA sequencing would, have 
made it possible.  
 
The aim of my doctoral thesis was to examine human skin regeneration and to 
develop ways to enhance wound healing, especially in burn wound treatment. The 
main goal was to characterize the gene expression transcriptome of human donor site 
wounds over time. Skin biopsies were collected from patients before and after split-
thickness skin graft harvesting. The first biopsy of intact skin was obtained 
immediately before the site was wounded by the graft harvest. Immediately thereafter, 
a second biopsy was performed to serve as a sample an of acute wound. Later, the 
next biopsies were obtained on the 3rd, 7th, 14th and 21st postoperative days. The skin 
graft donor site wound was chosen because it is controllably made in the operating 
room and represents a normal, uncomplicated, and consistently healing superficial 
skin wound. Negative pressure was applied to some of the donor sites to clarify the 
effects of this widely used therapy on gene expression in a healing wound. Moreover, 
this approach enabled the initial evaluation of the gene expression profiling principle 
for clinical research purposes. 
 
The tissue samples collected were homogenized, and ribonucleic acid (RNA) was 
isolated. Thereafter, genomewide microarrays were performed on all samples. The 
gene profiles at different time points were compared, and data were presented as fold-
change alterations in gene expression. As a result, the data reveals various types of 
gene expression patterns relating to, loss of expression due to tissue removal, down-
regulation or induction of expression as the wound-healing cascade advances or 
regain of expression according to tissue regeneration. The results also give molecular 
level information on the effects of negative-pressure wound therapy. 
 
 
These studies provide the first insights into the transcriptome during normal human 
superficial cutaneous wound healing. The data reveal novel genes associated with 
epidermal wound healing. Moreover, they provide a fundamental background for 
future studies that can be utilized in the clinical evaluation of the effects of therapies. 
  
 
  
 	
1. Introduction 
 
Wound-healing capability is essential for survival. Millions of people around the 
world suffer from severe nonhealing wounds and hundreds of millions of euros are 
spent annually on treatments that unfortunately are too often inefficient (Sen et al., 
2009). Two major causes tightly associated with compromised wound healing, 
namely population aging and the increased prevalence of obesity, have caused an 
alarming increase in this load. These concerns further stress the desperate need to find 
efficient new solutions for wound repair (Graham et al., 2003). 
  
The complex process of wound healing is divided into three overlapping phases of 
inflammation, new-tissue formation and tissue remodelling (Reinke & Sorg, 2012). It 
has been studied for decades, and over the years researchers have been able to 
establish many molecular components involved in its underlying mechanisms. 
However, comprehensive studies on molecular detail are an unfortunate rarity in 
humans (Cole et al., 2001; Greco et al., 2010; Smiley et al., 2005). Many wound- 
healing data are still obtained from different animal models (Sullivan et al., 2001; 
Zcharia et al., 2005). Although rodents provide valuable information, the fact that a 
mouse is not a man remains. 
 
It is challenging to study the process of wound healing in humans. Naturally, research 
must always be conducted on patients’ terms and conditions. Opportunities to have 
control wounds and to obtain numerous and ample tissue samples for analysis, as in 
animal studies are very limited. The lack of proper controls complicates objective 
evaluation of therapies; all patients are different and all wounds are different. In 
addition, several other factors, such as age and accompanying diseases, strongly 
influence the efficacy of wound healing (Broughton et al., 2006). 
 
As mentioned, novel therapies alongside traditional wound care are required. And, 
indeed, novel approaches such as various cell -, growth factor (GF) - and gene 
therapies are emerging. Several bioengineered skin products, as well as cell therapy 
products, are already on the market and have been proven to be helpful (Günter & 
Machens, 2012). The next challenge is to make these treatments available. Yet, the 
promising therapies have failed, due to their complexity or, even more commonly due 
to their ridiculously expensive prices. Thus, products should be practical for doctors 
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and nurses to use and, more importantly they should be affordable and effective. 
Future evolution in automated cell culture techniques, as well as rationalization of 
bureaucratic protocols, will help to solve these issues.  
 
The goal of the first three studies in my doctoral dissertation was to provide novel 
insight into the molecular associations behind human cutaneous wound healing by 
mapping the gene expression profile of repair over time. The approach was to use skin 
graft donor site wounds that heal reliably, are clean and of standard depth for the 
characterization of gene expression. Punch biopsies of patients’ wounds were 
collected over time, and the transcriptome at each time point was obtained, using 
commercially available comprehensive gene expression microarray chips. This 
approach will enable the established theories of the wound-healing cascade to be 
examined, challenged and extended, using the full human genome. In addition to 
giving abundant new information for research purposes, these data will be utilized as 
a clinical research tool to enable objective evaluation of human donor site wound 
healing.  
   
In the fourth study the properties of human recombinant collagen III (rhCol-III) as a 
dermal filler and a carrier of autologous cells were examined. Cell viability inside the 
gel was examined in vitro and the in vivo properties were evaluated in porcine full-
thickness wounds.  
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2. Review of the literature 
 
2.1 Skin structure, function and homeostasis 
 
Skin is the largest organ in the human body. It has a layered structure that is essential 
for a multitude of functions (Figure 1). Skin also contributes to our appearance and 
shape. It greatly affects our mental wellbeing through aesthetic and cultural 
influences. More importantly, the skin serves as a shield that protects us from the 
outside world. All layers of the skin (epidermis, dermis and hypodermis) serve as 
sentinels against various physical, biological and chemical threats (McLafferty et al., 
2012). Skin is an important part of the immune system and contains components of 
both the innate and adaptive immune systems. Moreover, with its numerous nerve 
endings, the skin serves as a sensory organ by mediating sensations of heat, pressure, 
and pain to the central nervous system. Through various exocrine glands and a highly 
versatile capacity to regulate its blood flow, the skin contributes to regulation of body 
temperature (Hannuksela et al., 2003). The skin is also an endocrine organ and 
participates in the production and metabolism of vitamin D3. Finally, the skin helps us 
to express feelings by reflecting the various actions of the autonomic nervous system, 
such as through vasolidation-blushing (Calonje et al., 2011). 
 
Skin is constantly stressed by threats from the outside world. Production of 
antimicrobial peptides (AMPs) that contribute to the killing of bacteria, viruses, and 
fungi is the primary protection system against microbes, and during microbial 
invasion expression of AMPs increases. The AMPs protect either directly by killing 
microbes or indirectly by signalling host response through GF, chemotactic and 
angiogenic activity (Schauber & Gallo, 2009). Indirectly acting AMPs are also known 
as alarmins. Many cell types (such as keratinocytes, sebocytes and mast cells) that 
reside in the skin produce AMPs. Moreover, inflammatory cells patrolling or 
infiltrating the skin also contribute to production of AMPs (Chan et al., 2012). For 
killing, AMPs target various microbial structures in the membranes or in the 
cytoplasm. They can also cause targeted disruption of bacterial metabolic pathways. 
Their initial targeting to the microbes relies on their positive charge against negatively 
charged microbes. There are over 20 cutaneous AMPs of which β-defensins and 
cathelicidins are the most well known (Yang & Oppenheim, 2004). AMPs are 
 

structurally very diverse and thus their antimicrobial activity is the only admission 
requirement. Some of the AMPs are secreted in the uppermost layer the of epidermis, 
such as the Escherichia coli-killing S100 calcium-binding protein A7 (S100A7, 
psoriasin) and ribonuclease 7 (RNASE7). However, most of the AMPs reside in the 
living layers of the skin (Brogden, 2005).  
 
In addition, the skin’s immune system consists of antigen-presenting Langerhans 
cells, lymphocytes, mast cells and keratinocytes. Langerhans cells are dendritic cells 
that stretch out and establish connections with keratinocytes. They register early 
injury or infection and relay the message to other members of the immune defence. 
Langerhans cells together with various lymphocytes induce the adaptive immune 
response. As for keratinocytes, in the absence of injury they secrete several inhibitory 
cytokines, such as GF and interleukins (ILs), and in response to injury they stimulate 
inflammation and activate Langerhans cells (Williams & Kupper, 1996). Mast cells 
are important effector cells in the induction of an inflammatory response. They also 
take part in the pathogenesis of various inflammatory disorders, such as 
immunoglobulin E (IgE)-mediated allergies and autoimmune disorders (Maurer et al., 
2006).  
 
Skin has a strong ability to renew itself. However, for it to function normally there 
must be a balance between generation of new cells and desquamation of dead cells. In 
a continuously undergoing process, new epidermal cells are produced in the basal 
layer, while old dead keratinocytes are sloughed off from the surface. The life of a 
newborn keratinocyte begins in the basal layer, once it commits to the predetermined 
programme of differentiation (Figure 2) (Blanpain & Fuchs, 2009). Subsequently, the 
cell begins its journey towards the surface of the skin. It migrates through the various 
layers, during which the supply of nourishment decreases; the cell accumulates 
keratin (KRT), and eventually dies. After about 1 month, the terminally differentiated, 
already dead cell reaches the surface and is sloughed off. Taken together on a cell 
population level, this process is called epidermal homeostasis, and epidermal stem 
cells are responsible for its maintenance. In the skin, these stem cells reside in the hair 
follicles, in the stratum basale of the epidermis, and in the sebaceous glands and 
sweat glands (Fuchs, 2007; Rittié et al., 2013). 
 

 
 
 
 Figure 1. Structure of skin. A. Different layers of the skin and its appendages 
(Adapted from Böttcher-Haberzeth et al., 2010). B. Structure of the epidermis 
(Adapted from Polat et al., 2010). 
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2.1.1 Epidermis 
The epidermis is the outermost layer of the skin (Figure 1). The majority of its cells, 
about 90%, are keratinocytes, but it also contains melanocytes, Langerhans cells, 
Merkel cells and some inflammatory cells. It is avascular and thus dependent on the 
blood vessels of the underlying dermis to secure its metabolic demands. The thickness 
of the epidermis varies from 0.5 mm in the eyelids to 4 mm in the palms of the hands 
or even thicker in the soles of the feet. Counting outward from the dermis, the five 
histologically distinguishable layers of the epidermis are: stratum basale, stratum 
spinosum, stratum granulosum, stratum lucidum, and stratum corneum (SC) (Figure 
1B) (Calonje et al., 2011). The epidermis renews itself through cell division in 
stratum basale from where cells start their journey towards the surface of the skin. 
Each layer represents a different stage in the life of an epidermal cell (Blanpain & 
Fuchs, 2006). 
 
To form a barrierlike structure, the epidermal cells inter connect by different types of 
intercellular junctions. In the living layers of the epidermis (from the stratum basale 
to the stratum granulosum), the cells link with each other via desmosomes, adherens 
junctions and tight junctions (Morita et al., 2011). In the SC, cell-cell connections are 
formed by corneodesmosomes. Adherens junctions are intercellular protein structures 
that are located at cell-cell junctions in all layers of the epidermis, except the SC.  In 
addition to keeping epithelial cells together, they regulate many cellular processes, 
such as cell shape, cell division, growth, apoptosis and barrier function. They are 
composed of cadherin and catenin components. The transmembrane part of the 
junction consists of Ca2+-dependent E- and P-cadherins, while the plaque is made of 
plakoglobin (δ-catenin), p120 (γ-catenin), α-catenin and β-catenin (Brandner et al., 
2010). Desmosomes constitute the major intercellular adhesion complex in the 
epidermis, since they anchor KRT intermediate filaments to the cell membrane and 
link adjacent keratinocytes. There are three main desmosomal protein components: 
the desmosomal cadherins, the armadillo family of nuclear and junctional proteins, 
and the plakins. The desmosomal plaque proteins (desmoplakin, plakoglobin, 
desmoglein, desmocollin, plakophillin, KRT) and transmembranous molecules create 
a structural and signalling bridge between the cells (Green & Simpson, 2007). 
Desmosomes connect the cells in all layers of the epidermis, except in the SC, where 
the morphology and layered structure of the desmosomes become altered, and they 
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are transformed into corneodesmosomes. They also lose the intercellular part of the 
junction, and the intracellular plaque embeds within the cross-linked cornified 
envelope (CE). Corneodesmosomes remain functional and eventually are the main 
structure that must be broken before the differentiated cells can slough off in 
desquamation (Jonca et al., 2011). Tight junctions are cell-cell junctions that in the 
skin are mainly located in the stratum granulosum layer of the epidermis. They are 
composed of transmembrane proteins (e.g. claudin 1 - 24, occludin, tricellulin), 
junction adhesion molecules, and intracellular scaffold proteins (e.g. zona occludens 
proteins 1 - 3 (ZO-1-3) and cingulin). Tight junctions form the main barrier against 
solute permeation in the human epidermis (Kirschner et al., 2010).  
 
The stratum basale is the innermost layer of the epidermis, and normally comprises a 
single row of columnar keratinocytes that divide through mitosis (Figures 1B and 2). 
It is the only layer in which the epidermal cells can divide. The proliferation of basal 
cells is dependent on the underlying basement membrane (BM), which is rich in 
proteins and GFs (Fuchs, 2009). New epidermis is constantly formed by epidermal 
stem cells of this layer; the cells divide, commit to differentiation and migrate towards 
the upper layers. However, for the skin to function normally, the stem cells must 
accomplish a dual task of self-renewal and generation-differentiated cells. It is 
believed that there are two distinct strategies of cell division to maintain the balance 
between stem cells and their differentiated progeny: asymmetric and symmetric cell 
division. In asymmetric cell division, the stem cells divide in the basal layer and form 
two identical daughter cells, one of which remains as a stem cell while the other 
commits to a terminal differentiation programme. As for symmetric cell division, each 
stem cell divides symmetrically to form either two daughter stem cells or two 
differentiating cells. An evolved third strategy could be the sequential combination of 
these two: cells could divide either asymmetrically or symmetrically (Blanpain & 
Fuchs, 2009; Morrison & Kimble, 2006). Thus, in addition to stem cells the basal 
layer contains committed progenitor cells, also known as transit-amplifying cells. 
They divide frequently, but for a limited number of cycles, before they undergo 
terminal differentiation.  
 
Many pathways and genes regulate skin homeostasis. Research so far has identified 
two of the most important pathways involved: Wnt and Notch. The Wnt pathway 
favours the maintenance of stem-cell characteristics and thus inhibits the switch to 
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transit-amplifying cells, whereas Notch signalling is believed to have a contrasting 
effect (Honeycutt & Roop, 2004; Okuyama et al., 2008). The proliferative potential of 
basal cells correlates with the expression of beta 1 integrin (ITGB1). Hence, stem 
cells express more ITGB1 than transit cells. c-Myc, transforming growth factors beta 
(TGF-β) and alpha (TGF-α), and p63 also regulate the proliferation of epidermal stem 
and transit cells. Cells in the basal layer typically express KRTs 5 and 14. These 
structural proteins together with tubulin and actin form the cytoskeleton of the 
epithelial cells (Blanpain & Fuchs, 2009; Watt, 1998). In addition, there are also 
melanocytes and Merkel cells in the basal layer. Melanocytes produce melanin, a 
pigment material that defines the colour of our skin. They comprise about 8% of the 
cells in the epidermis. The skin protects us from ultraviolet (UV) radiation by 
accelerating the function of melanocytes. In melanocytes, melanin is produced and 
stored in specialized cell organelles called melanosomes (Marks & Seabra, 2001). 
After the melanosomes are packed with melanin, the melanocytes release them to 
large numbers of nearby keratinocytes through a network of cytoplasmic extensions, 
or dendrites that open up throughout the intercellular spaces of the lower epidermis. 
When the skin is irradiated with ultraviolet B (UVB) radiation, more melanosomes 
form and their transport to the keratinocytes becomes more efficient (Hume & Seabra, 
2011). As for the Merkel cells, they are oval receptor cells responsible for sensation 
of touch (Calonje et al., 2011).  
 
From the basal layer, cells committed to terminal differentiation migrate first to the 
stratum spinosum where they change their shape to more round and spinous and also 
lose their ability to divide (Figures 1B and 2) (Fuchs, 2007). The stratum spinosum is 
5 - 12 cells thick and the cells are attached to each other through adherens junctions, 
desmosomes and tight junctions. As the cells move through this layer, the junctions 
break and reform continuously (Kirschner & Brandner, 2012). Here, the cells switch 
off genes encoding KRTs 5 and 14 and begin expressing KRTs 1 and 10 to form even 
stronger intermediate filaments that link together with desmosomes. In the upper 
layers, KRT 2 expression is also switched on (Kurokawa et al., 2011). In addition, 
Langerhans cells lodge in this layer. These cells are formed of specialized dendritic 
cells of the immune system in the red bone marrow, from where they migrate to the 
stratum spinosum, and act as an important player in the immunologic defence against 
microbes. Moreover, vitamin D is produced in the two innermost layers of the 
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epidermis, in the stratum basale and stratum spinosum. UVB radiation transforms the 
skin’s dehydrocholesterol into previtamin cholicalciferol, which develops further into 
vitamin D in the liver and kidneys (Bikle, 2011).  
 
The next layer is the 3 - 5-cell-thick stratum granulosum (Figures 1B and 2). When 
the cells reach this layer, they have become longer and flattened and are known as 
granular cells. Here, the cells undergo apoptosis and lose their metabolic activity. 
They also lose their nucleus and other cell organelles and become comprised of 
fibrous KRT and keratohyalin. Despite this, the cells retain their transcriptional 
activity. The granular cells secrete proteins containing lysine and glutamate, which 
bond together in a process catalysed by transglutaminases (TMGs) 1, 2 and 5 and 
form the CE. The CE is a protein-rich structure surrounded by a lipid envelope that 
replaces the plasma membrane in the differentiated keratinocytes (Figure 2). It 
provides a vital mechanical and permeability barrier to the skin. There are several 
proteins present in the CE, including loricrin (LOR), involucrin (IVL) and the family 
of small proline-rich (SPRR) proteins, as well as the S100 proteins. Other CE proteins 
include filaggrin (FLG), late-cornified envelope (LCE) proteins, elafin (peptidase 
inhibitor 3 (PI3)) and various KRTs (such as KRT2, 9 and 10) (Candi et al., 2005). 
Very interestingly, many genes regulating important functions of late epidermal 
differentiation are located in the same cluster of genes in human chromosome 1q21, 
known as the epidermal differentiation complex (EDC) (Marenholz et al., 2001).  
 
Genes in the EDC belong to three families encoding 1) precursor proteins of the CE, 
2) calcium-binding proteins of the S100A family and 3) intermediate filament-
associated proteins. IVL, LOR, SPRR proteins, and LCE proteins are the main 
precursors of the CE. The second group, the S100A family, consists of 17 genes and 6 
pseudogenes, all of which contain EF-hand domains. Generally, the S100 proteins 
regulate different steps of the calcium signal transduction pathway and affect cell 
shape, cell cycle and differentiation. Genes in the third family are fusion genes 
evolved from the other two EDC gene families (Mischke et al., 1996). Members of 
the fused gene family include FLG, repetin (RPTN), hornerin (HRNR) and cornulin 
(CRNN), which are large cytoplasmic matrix proteins linked with intermediate 
filament proteins and smaller components of the CE. Importantly, many skin diseases, 
such as atopic dermatitis, psoriasis, ichthyosis vulgaris, Vohwinkel’s syndrome and 
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progressive symmetric erythrokeratoderma, have been associated with mutations in 
the EDC genes for inherited predisposition (Kypriotou et al., 2012). 
 
The next layer, the transparent stratum lucidum (Figures 1B and 2), exists only in 
areas where the epidermis is thickest, as in the palms of the hands or in the soles of 
the feet. It comprises 3 - 5 layers of flat and clearly dead keratinocytes that are made 
up mostly of KRT. This layer provides some degree of waterproofing to the skin 
(Calonje et al., 2011). 
 
 
 
Figure 2. Skin homeostasis and barrier development (Adapted from 
http://www.pgbeautygroomingscience.com). 
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The SC is the endpoint of terminal differentiation (Figures 1B and 2). It is composed 
of 25 - 30 layers of flattened dead-cell remnants, called corneocytes. They are inter  
connected by corneodesmosomes. The cells contain KRT, which protects skin and the 
tissues below from heat and chemicals. They also lose the intercellular part of the 
junction, and the intracellular plaque embeds within the cross-linked CE. The 
corneodesmosomes remain functional and eventually are the last structures to be 
broken before the differentiated cells are sloughed off by desquamation (Menon et al., 
2012). 
 
 As stated above, one of the main responsibilities for the skin is to offer mechanical 
strength and form an epidermal barrier. Terminal differentiation of the epidermal cells 
and most importantly the proper development and maintenance of the SC are the 
demands for barrier formation. An intact and healthy corneal layer efficiently blocks 
the entry of various microorganisms deeper into the body and reduces the absorption 
of chemicals from the environment (Madison, 2003). The SC almost completely 
prevents the evaporation of water through the skin. The corneocytes secrete their 
intracellular lipid, which attaches cells together and prevents them from drying. The 
lipid composition of the SC is an equimolar mixture of ceramides, cholesterol and 
free fatty acids (Yardley & Summerly, 1981). When cells push through the SC they 
lose their stickiness and slough off, either singly or in clumps (Wickett & Visscher, 
2006).  
2.1.2 Basement membrane 
Cells of the basal layer reside on a BM, which is the border between the epidermis 
and dermis. The BM is a ubiquitous sheetlike deposition of the extracellular matrix 
(ECM). The major components of the BM are type IV collagen, laminin, heparin 
sulphate proteoglycan and entactin. Mesenchymal and epithelial cells secrete the 
components of the BM and are thus responsible for its synthesis and development (Ko 
& Marinkovich, 2010). Although its main function is to anchor the cells of the 
epidermis to the underlying dermis, interactions between the BM components and 
epithelial cells have an important impact on cell function, including proliferation, 
migration, and differentiation. The BM is also a significant factor in angiogenesis and, 
thus, its proteins accelerate the differentiation of endothelial cells. Structurally, it is 
divided into an upper basal lamina and a lower reticular lamina. The basal lamina 
itself consists of a complex network of interacting macromolecules and has two 
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layers: the lower lamina densa and upper lamina lucida. Many of these components 
are glycoproteins, and various collagens, laminins and integrins. The main adhesion 
unit at the dermal-epidermal junction is a hemidesmosome-anchoring, filament-
anchoring fibril complex that forms a continuous structural link between the basal 
keratinocytes and subjacent dermal components (Breitkreutz et al., 2009). In addition, 
there are protein-protein interactions between these molecules to secure adhesion 
between the epidermis and subjacent dermis. The main component of the anchoring 
fibrils is type VII collagen and that of the lamina densa is type IV collagen. Lower 
reticular lamina is a thin layer of the ECM that sometimes lies below the basal lamina. 
It is mainly composed of collagenous fibres, and connects the basal lamina to the 
dermis. In addition, at the bottom of the stratum basale epidermal thickenings, 
undulating rete ridges anchor the epidermis to the papillary region of the dermis. 
These ridges also develop fingerprint patterns on the fingertips (Furuyama & 
Mochitate, 2000). 
2.1.3 Dermis 
The dermis is the zone between the hypodermis and epidermis. The major cell types 
of the dermis are fibroblasts, macrophages and adipocytes. Its main functions are to 
supply nutrients to the epidermis, regulate temperature and provide a mechanically 
tough elastic supporting layer. The dermis is also responsible for the skin’s tensile 
strength. Structurally, it can be divided into two layers: an upper papillary layer and a 
lower reticular layer. Nerve endings and capillaries that nourish the epidermis are 
located in the superficial papillary layer. Beneath that is the reticular layer, which, 
like the dermis is made of strong connective, whose main structural elements are 
collagen and, elastic fibres. The most abundant component of the ECM in the dermis 
is collagen, especially collagen types I (80%) and III (10%). Although some mature 
collagens are rather stable and may remain unaltered in tissues for lengthy periods, a 
continuous process of loss and replacement of collagens is orchestrated by the matrix 
metalloproteinase (MMP) enzyme family. In the skin, MMPs are secreted by 
fibroblasts and keratinocytes and are divided into collagenases (e.g. MMP1), 
gelatinases (e.g. MMP2), matrilysins (e.g. MMP7), stromelysins (e.g. MMP13), and 
membrane-type MMPs  (e.g. MMP14). They play an important role in tissue 
remodelling and therefore their expression is increased, e.g. during wound healing. 
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Matrix components, collagen and elastin provide strength and elasticity to the skin 
and are mainly secreted by fibroblasts (Calonje et al., 2011; Hannuksela et al., 2003). 
 
The dermis is rich in blood vessels and is responsible for nourishing the acellular 
epidermis. Several arterioles extend from the subcutaneous fat to the dermis and form 
a network of blood vessels called the deep vascular plexus. These vessels deliver 
blood to the various parts of the dermis and subcutaneous tissue. In addition, small 
branches from this plexus nourish the hair follicles and sebaceous glands. Small 
arterioles (and their corresponding venules) connect the deep vascular plexus with 
another network of cutaneous blood vessels called the superficial vascular plexus, 
which provides blood to the epidermis. Apart from nourishment, cutaneous blood 
flow is also crucial to thermoregulation (McLafferty et al., 2012). 
 
Skin appendages, various glands and hair follicles are also important components of 
the dermis. There are two kinds of glands in the dermis: sweat glands and sebaceous 
glands. Sebaceous glands are especially abundant on the face, neck and scalp and are 
often connected to the hair follicles. They secrete a greasy solution called sebum that 
covers the hair and skin and protects it from drying. It also controls epidermal water 
loss, and is believed to have some antimicrobial properties (Kanitakis, 2002). Sweat 
glands are divided into eccrine glands and apocrine glands. There are many more 
eccrine glands and they are found everywhere on the skin, but are particularly 
abundant on the face area, palms, and soles. Both physical and mental stress 
accelerates these glands’ functions. Eccrine glands are believed to play an important 
role in epidermal repair by generating keratinocyte outgrowths that ultimately form 
new epidermis (Rittié et al., 2013). Apocrine glands are mostly found in the 
anogenital and axillary regions. Their function is not understood. Hair is produced in 
hair follicles that reside either in the dermis or in the subcutaneous fat layer, and are 
present on almost all surfaces of the human body (Calonje et al., 2011).  
 
In addition to in the stratum basale, skin stem cells are also located in these 
appendages. The hair follicle stem cells are located in the bulging regions of the 
follicle and are responsible for the uninterrupted renewal of hair follicles. First, they 
differentiate into highly proliferative matrix cells that further differentiate either into 
hair shaft cells or inner root sheath cells. Hair stem cells are also capable of forming 
new epidermal cells, but this only occurs when the skin is wounded. In addition to 
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hair follicle stem cells, there are also melanocyte stem cells located in the hair 
follicles. These cells are involved in hair pigmentation. Stem cells in sebaceous 
glands differentiate into sebocytes that form new sebaceous glands and secrete sebum 
(Boehnke et al., 2012). 
2.1.4 Hypodermis 
Underneath the dermis is the hypodermis, also known as the subcutis, the deepest 
layer of the skin. It is fat tissue that is divided into small lobes developed by fibrous 
walls or septae. The cells found in this layer include adipocytes, fibroblasts and 
macrophages. The function of the hypodermis is to act as a ligament between the skin 
and other tissues, such as muscles. It protects the body from impacts, is also involved 
in thermoregulation and serves as a nutritional storage.   
 
There are about 1 million sensory afferent nerve fibres in the skin. They are unevenly 
distributed in the body, most of them conveying tactile sensations from the face and 
hands/feet, with relatively few supplying the back. The main nerve trunks are in the 
hypodermis, where they divide into smaller branches that enter the dermis and in 
some cases even the basal layer of the epidermis (Reinisch & Tschachler, 2005). 
Neurons in the skin are divided according to their modality. There are touch-, 
pressure-, and vibration-sensing mechanoreceptors, cold- and warm-sensing 
thermoreceptors, as well as pain-sensing nocireceptors in the skin. Mechanoreceptor 
axons are all myelinated and they include the Pacinin corpuscle, Meissner corpuscle, 
Raffini corpuscle, Merkel disk and hair follicle receptor. Cold receptors have a small 
myelinated axon that reaches out to the epidermis; while warm receptors have a 
shorter unmyelinated axon. They both activate when the skin’s temperature diverts 
from its normal levels. In addition, there are rapid nocireceptors, whose myelinated 
axons stretch to the epidermis side, and slow nocireceptors with shorter and 
unmyelinated axons (Boulais & Misery, 2008). 
 
2.2 Wounds and healing 
 
Chronic wounds and compromised wound healing are major concerns for the public 
health sector. Complex and lengthy treatments cause an increasing burden on 
healthcare expenses. Deep burns, chronic and other difficult-to-treat wounds require 
surgery and extended hospitalization periods. In the United States every year 6.5 
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million patients need treatment for chronic wounds and an estimated US $25 billion is 
spent annually. More worryingly, the burden is growing yearly mainly due to the 
increasing incidence of obesity and diabetes (Sen et al., 2009). 
 
2.2.1 Acute wounds 
Wounds are usually divided into acute and chronic wounds. Acute wounds are 
traumatic or surgical wounds and usually heal within a foreseeable period of time 
according to normal wound-healing processes. Acute wounds vary from superficial 
scratches to deep wounds that damage blood vessels, nerves, muscles or other tissues 
or internal organs (Percival, 2002). 
 
Acute wound healing is a complex physiological process that is regulated by many 
different cell types, several GFs, cytokines and chemokines. Most of all, it is the 
body’s inherent way of responding to an injury. During the healing process, cells such 
as many inflammatory cells, platelets, endothelial cells, fibroblasts and keratinocytes 
undergo distinct preprogrammed changes in their gene expression and phenotype. In 
consequence, the cells begin to migrate, proliferate and differentiate, which leads to 
inflammation response, new-tissue formation and finally tissue remodelling; in other 
words to the classical phases of wound healing (Figure 3) (Gurtner et al., 2008). 
  
The wound-healing programme is an intricate interplay between several cell types 
involving various forms of intercellular signalling. The most important cells and GFs 
involved in wound healing are shown in Table 1. Most wounds heal rather quickly 
and efficiently within weeks, according to the phases of normal wound healing 
(Martin, 1997).  
 
The immediate response to injury is haemostasis, which is achieved by formation of a 
fibrin mesh or clot in a process that is regulated by the coagulation cascade and 
constriction of vessel walls. Fibrin provides a temporary cover and acts as a matrix 
that aids cell migration during healing. In addition, it binds and stores GFs and 
cytokines (Gurtner et al., 2008). More importantly, platelets trapped inside the clot 
secrete several GFs, such as platelet-derived growth factors (PDGFs), epidermal 
growth factors (EGFs), insulinlike growth factors (IGFs) and TGF-β. The release of 
these signalling proteins accelerates the wound healing process by activating 
fibroblasts, endothelial cells and inflammatory cells (Enoch & Leaper, 2008). 
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 Inflammation is the first actual phase of wound healing. It occurs immediately after 
cell damage and lasts for about 2 - 3 days (Figure 3). The immune defence is 
activated: the complement system activates, neutrophils migrate to the wound, 
platelets degranulate and bacteria degrade. The presence of various chemoattractants, 
such as complement components, TGF-β, ECM protein fragments and products from 
bacteria attracts neutrophils to the wound site within the first 24 - 48 hours after 
wounding. Infiltrating neutrophils clear the wound site of pathogens and are then 
cleared either passively in an eschar or through active phagocytosis by macrophages. 
Later on, about 2 days after the injury in the late phase of inflammation, monocytes 
emerge in the wound, also attracted by numerous specific chemoattractants. 
Monocytes infiltrate the wound area and differentiate into macrophages that initiate 
the formation of granulation tissue. Thus, being an important part of the inflammatory 
process macrophages also act as key regulatory cells for repair. The GFs and 
cytokines (e.g. TGF-α, TGF-β, PDGF, IGF, IL-1) that they produce are responsible 
for proliferation and production of ECM, fibroblasts, smooth-muscle cells and 
endothelial cells. (Singer & Clark, 1999) 
 
New-tissue formation occurs 2 - 10 days after injury (Figure 3). An eschar is formed 
and epithelial cells migrate underneath. Keratinocytes migrate over the damaged 
dermis and new blood vessels form in angiogenesis, which is induced by several 
factors such as vascular endothelial growth factor A (VEGF-A), fibroblast growth 
factor 2 (FGF-2), PDGF, and TGF-β. Angiogenesis is necessary for formation of new 
granulation tissue. A legion of new capillaries provides nutrients and oxygen to the 
growing tissue and takes care of waste disposal. Equally important factors are 
macrophages that supply GFs for angiogenesis and fibroplasia and new ECM-
producing fibroblasts. In 3 - 5 five days after injury, new granulation tissue is well 
established and replaces the fibrin clot (Gurtner et al., 2008). About 2 - 4 days after 
injury, fibroblasts appear in the wound. They migrate either from bone marrow or 
from the wound edges and several GFs, including PDGF and TGF-β, attract their 
movement. In the wound, fibroblasts form the new ECM by producing various ECM 
proteins (e.g. fibronectin, hyaluronan) and later on collagen and proteoglycans. 
Subsequently, macrophages stimulate fibroblasts in the wound and some differentiate 
into myofibroblasts. These cells contract and eventually close the wound together 
from the edges (Barrientos et al., 2008; Gurtner et al., 2008). 
 
 
 
Figure 3. Classical steps in wound healing (Adapted from Gurtner, 2008): A. 
Inflammation, B. Tissue remodelling and C. New-tissue formation. 
  
 
Table 1. Main wound-healing-related growth factors (GFs) and cytokines, their function, 
secreting cells, and their expression in both acute and chronic wounds (+, increased; -, 
decreased).  
Abbreviations: EGF, epidermal GF; FGF, fibroblast GF; HGF, hepatocyte GF; KGF, 
keratinocyte GF; PDGF, platelet-derived GF; TGF, transforming GF; VEGF, vascular 
endothelial GF; IL, interleukin; TNF, tumour necrosis factor. 
 
 
 
 
 
 
 
 
 
 
 
 
GF Function Cells Acute  Chronic 
          
EGF Re-epithelialization Platelets, Macrophages, 
Fibroblasts 
+ - 
          
FGF-1, 2 Granulation tissue formation, Re-
epithelialization, Matrix formation, 
Remodelling 
Keratinocytes, Mast cells, 
Fibroblasts, Endothelial cells, 
Smooth-muscle cells, 
Chondrocytes 
+ - 
          
HGF Epithelial and endothelial cell 
proliferation, Hepatocyte motility 
Mesechymal cells + - 
          
KGF Keratinocyte proliferation, differentiation, 
migration 
Keratinocytes + - 
          
PDGF Inflammation, Granulation tissue 
formation, Re-epithelialization, Matrix 
formation, Remodelling 
Platelets, Keratinocytes, 
Macrophages, Endothelial cells, 
Fibroblasts 
+ - 
          
TGF-β Inflammation, Granulation tissue 
formation, Re-epithelialization, Matrix 
formation, Remodelling 
Platelets, Keratinocytes, 
Macrophages, Lymphocytes, 
Fibroblasts 
+ - 
          
VEGF Granulation tissue formation Platelets, Keratinocytes, 
Macrophages, Endothelial cells, 
Smooth-muscle cells, Fibroblasts 
+ - 
          
Cytokines         
          
IL-1 Inflammation, Re-epithelialization Neutrophils, Macrophages, 
Monocytes, Keratinocytes 
+ + 
          
IL-6 Inflammation, Re-epithelialization Neutrophils, Macrophages + + 
          
TNF-α Inflammation, Re-epithelialization Neutrophils, Macrophages + + 
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A major event in the new-tissue formation phase is re-epithelialization, which is a 
combination of keratinocytes migrating and proliferating in the wound. Basal 
keratinocytes migrate from the wound edges as well as from the skin appendages to 
the injured area to form a fragile cover over the wound, in a process called epiboly. 
Cells undergo phenotypic alterations to ease the migration towards the provisional 
wound matrix. Firstly, they must disassemble most of the intercellular desmosomes 
and hemidesmosomes, which involves the rearrangement of integrin receptors. They 
also retract their intracellular tonofilaments and KRT filaments and form focal 
contacts, as well as cytoplasmic actin filaments that allow cell movement. In addition, 
the ECM must be broken down to allow cell migration between the collagenous 
dermis and fibrinous eschar. To degrade the ECM, the epidermal cells produce MMPs 
(collagenases) and plasminogen activators. The normally firm attachment to the 
underlying dermis is now loosened and keratinocytes migrate in a leapfrog fashion 
across the provisional matrix. Some hours after the onset of migration, the cells begin 
to proliferate strongly to replace the cells that were lost in the injury. Finally, 
migration is halted by contact inhibition when the advancing keratinocytes from both 
edges of the wound meet. Further growth and differentiation of the cells re-establishes 
the stratified epidermis with the underlying basal lamina. Re-epithelialization begins 
within hours after injury and is regulated by several GFs.  
 
One of the most important molecules associated with re-epithelialization is HGF 
(Table 1). It promotes both keratinocyte migration and proliferation. HGF mediates its 
functions by binding to a membrane receptor tyrosine kinase, c-Met, that is essential 
for wound repair. When activated by HGF, it induces a process called invasive growth 
that in wound healing regulates inflammation and tissue remodelling (Gentile & 
Comoglio, 2004). HGF’s important role in re-epithelialization supports results with 
HGF knockout mice, which have showed a robust consistent delay in re-
epithelialization of skin wounds when HGF is blocked. Other important re-
epithelialization-related GFs include members of the FGF and EGF families 
(Chmielowiec et al., 2007). In addition to keratinocytes, epidermal stem cells from 
skin appendages participate in the repair process. In response to wounding, they 
commit to terminal differentiation and migrate into the wound area (Shaw & Martin, 
2009). 
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The last stage—tissue remodelling—begins a couple of weeks after wounding and can 
last over 1 year (Figure 3). At this stage, most of the endothelial cells, macrophages 
and myofibroblasts go through apoptosis or leave the wound. The ECM of the 
damaged area consists mainly of collagen and other ECM proteins. During the first 6 - 
12 months after the injury, the ECM regenerates constantly, which strengthens the 
tissue. This process is orchestrated by various MMPs, which fibroblasts and other 
cells secrete. Although the wound heals, it will never again meet the qualities of an 
unharmed skin (Gurtner et al., 2008; Singer & Clark, 1999). 
 
2.2.2 Burns 
Burn wounds are acute wounds that are caused by heat, chemicals, electricity, 
sunlight, radiation or friction. Burns can be categorized into superficial (I°), partial-
thickness (II°) and full-thickness wounds (III°). The majority of burn wounds are 
superficial and involve only the epidermis. They are usually caused by UV radiation 
from the sun and heal well by themselves, without any sign of scarring (Johnsson & 
Richard, 2003). 
 
Partial-thickness burns are further divided into superficial and deep. Superficial 
partial-thickness burns extend through the epidermis and reach the upper papillary 
layer of the dermis. These wounds become erythematous, and thin fluid-filled blisters 
develop within minutes of the injury. Body fluid leaks on to the wound surface, due to 
the loss of the epidermal barrier, making the wounds moist. Deep partial-thickness 
burns, on the other hand, reach as far as the lower reticular layer of the dermis. The 
wound area is moist and may form blisters, similarly to superficial partial-thickness 
burns. (Johnsson & Richard, 2003) 
 
I° burns heal in 1 week without any additional procedures. Superficial II° burns 
undergo epithelialization similar to split-thickness donor sites from dermal 
appendages in 2 - 3 weeks with good functional and cosmetic results. Deep II° burns 
require weeks, even months, to re-epithelialize and result with prolonged pain and 
severe scarring. Skin grafting is needed to accelerate the wound cover. III° burns can 
heal only to some extent by epithelialization from the wound edges and by 
contraction, although they almost always need skin grafting (Herndon, 2012). 
 
A full-thickness burn extends throughout the depth of the skin into the hypodermis 
(subcutaneous tissue). It may also damage muscle, bone or interstitial tissue. Soon 
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after the injury, fluids and proteins, leaking from capillaries into the interstitial space, 
cause oedema. An immediate immunologic response to injury in large burns causes 
the systemic inflammatory response syndrome (SIRS) and accelerated metabolic 
demands, needing aggressive nutritional support (Johnsson & Richards, 2003). 
 
Deep and large burns require hospitalization and, without exception, surgical 
treatment. The gold standard is to excise the dead burnt tissue and replace it with 
split-thickness skin grafts (STSGs). In this process, the patient’s own healthy skin is 
harvested and subsequently transferred to the burnt site after resection of the dead 
tissue. Although efficient, it is associated with substantial problems, such as poor-
quality skin, infections, and scarring and lack of donor sites in large burns (Archer et 
al., 1998).  
 
In addition, the donor site skin should be appropriate for the recipient site. If the graft 
is harvested from a different part of the body, there is risk of colour mismatch. 
Moreover, in the case of a very large burn, the areas available for harvesting are very 
limited. In such cases, the available graft is usually extended by meshing. Meshing 
improves wound drainage and thus draft-take. However it compromises both the 
aesthetic and functional outcomes. As an adjunct treatment, cadaver skin, xenografts, 
various biomaterials or special dressings are commonly used to treat burns (Lindford 
et al., 2010). 
 
2.2.3 Chronic wounds 
Sometimes wounds do not heal according to the normal healing process or the healing 
is remarkably delayed. Wounds are defined as chronic when they have failed to heal 
in 3 months. They are not capable of closure or of regaining the anatomy and function 
of healthy skin. Conventionally, chronic wounds do not occur in healthy people. They 
are very often related to conditions such as obesity, diabetes, and old age (Harding et 
al., 2002). 
 
The biology of chronic wounds is still poorly understood. Chronic wounds do not 
follow the steps of the normal wound-healing process and remain in the inflammation 
phase. It is suggested that lack of GFs, imbalance between proteinases and their 
inhibitors or presence of too many senescent cells in the injured area may result in the 
inability of these wounds to heal. In addition, adequate angiogenesis is crucial for 
wound closure. This in turn regulates fibroblast ability to form granulation tissue, and 
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thus inadequate microvasculature can lead to chronic nonhealing wounds. This is 
especially common in diabetic patients (Mustoe et al., 2006). 
 
The majority of chronic wounds fall into three categories: pressure ulcers, venous 
ulcers, and diabetic ulcers. It has been proposed that the pathogenesis of impaired 
wound healing is based on four factors: bacterial colonization of the wound, 
ischaemia, aging and reperfusion injury. Bacteria are substantially involved in the 
pathogenesis of chronic wounds. An open wound becomes contaminated within the 
first few days from the surrounding skin. By comparing the wound exudate of chronic 
wounds with that of clean surgical wounds, it has been indicated that chronic wound 
exudate contains greater amounts of proinflammatory cytokines and proteases (Peirce 
et al., 2000). In addition, GF levels are lower in chronic wound exudate. The second 
factor, ischaemia, also impairs wound healing. It is known that wounds in the lower 
extremities will not heal if the partial oxygen pressure is less than 30 mmHg. Partial 
oxygen pressure affects the local blood flow, which in turn affects the arterial flow, 
arteriovenous gradients, capillary density and local tissue consumption. Reperfusion 
injury has also been considered as one of the major factors leading to impaired 
healing. Tissue reperfusion injury occurs upon restoration of blood flow after an 
ischaemic period. The absence of oxygen and nutrients causes a reduction in tissue 
metabolism that results in inflammation and oxidative damage. Usually chronic 
wounds occur in older people. The average age of a chronic wound patient is over 60 
years. Cells in chronic wounds are under constant and significant stress. The ability of 
aged patients to respond to altered cellular and systemic stress is weakened 
(Stojadinovic et al., 2005).  
 
Treatment of chronic wounds has been very challenging due to the wounds’ diverse 
aetiologies and pathological backgrounds. This has caused problems in identification 
of the specific molecular mechanisms behind impaired wound healing. Another 
challenging factor is that, chronic wounds do not exist in animals and thus knowledge 
has to come from the clinic. Chronic wounds are treated with different wound 
dressings that aim at promoting healing by making the wound environment more 
favourable (Lawall, 2012). Additionally, GFs can be administered topically to wounds 
to increase cell proliferation and angiogenesis. Autologous skin grafts and various 
biomaterials are commonly used, especially to treat venous ulcers (Peirce et al., 
2000). 
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One of the treatment options for chronic wounds in the clinic is negative-pressure 
wound therapy (NPWT). It is commonly used to improve skin wound healing and to 
accelerate wound bed preparation, especially when dealing with chronic and other 
difficult-to-treat wounds (Orgill & Bayer, 2011). The effect of negative pressure on 
wound healing is partially mediated through modification of the wound environment 
into a more favourable state for healing by removing exudates and debris. In deep 
lesions, the negative pressure also aids wound closure. The advantages of NPWT over 
conventional dressings include decreased tissue oedema, stimulation and formation of 
new granulation tissue, increased local blood flow and decreased bacterial load 
(Schintler, 2012). 
  
2.2.4 Fibrosis 
Fibroblast proliferation and excessive growth of granulation tissue may cause scarring 
and wound contraction (Leask et al., 2004). Wounds, especially, those that develop 
keloids and hypertrophic scars, heal not through regeneration but through fibrosis. 
The pathogenesis of fibrosis is a combination of several factors. Individual age, 
genetic/racial background and hormonal imbalance greatly affect the prevalence of 
keloids and hypertrophic scars. These are manifested in the common notion that some 
people get scars easier than others. The location of the wound plays a role in scar 
formation, e.g. the shoulders and chest are the most common skin sites for keloid 
formation. In addition, the size of the wound or degree of a burn wound, 
inflammation, tension exerted in the wound area and, in case of iatrogenic wounds, 
the surgical technique used also impacts scar formation. These factors alone and 
together lead to abnormal cellular response; cells secrete an abnormal pattern of GFs 
and there are not enough molecules required for apoptosis or for remodelling of the 
ECM. The major GFs involved in tissue repair and fibrosis are TGF-β, PDGF and 
VEGF. They accelerate the deposition of the ECM by inducing the expression of 
ECM proteins, such as collagen and fibronectin. Although the production of the ECM 
is crucial to establishing and maintaining the structural and mechanical integrity of 
the skin, the excessive deposition may result in scar pathology. Additionally, GFs 
decrease the expression of MMPs that are involved in the breakdown of the ECM 
(Joo & Seomum, 2008). Normally, when tissue repair is completed, GF activity is 
turned off; however, in scar tissue it is overexpressed and poorly regulated (Ignotz & 
Massagué, 1986). Thus, increased GF production results in fibroblast proliferation, 
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neovascularization and increased collagen and fibronectin synthesis. Animal studies 
utilizing anti-TGF-β antibodies and TGF-β knockouts have resulted in less fibrosis 
and enhanced re-epithelialization. The overproduction of GFs and decreased MMP 
activity, in turn, lead to abnormal wound healing and eventually to the formation of a 
scar. In addition to cosmetic harm, a more serious problem with scar tissue is that it 
lacks the original functionality and elasticity of skin and causes contracture (Wolfram 
et al., 2009).  
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2.3 Skin tissue engineering 
 
Tissue engineering (TE) is a field of science that combines engineering and medicine 
to find new ways to improve regeneration and regain organ or tissue function. In the 
concept of TE, cells, materials and biological factors are used separately or combined 
(Figure 4) (Berthiaume et al., 2011; Stoltz et al., 2012). 
 
New tools are needed to lighten the massive and constantly increasing load of wounds 
and wound healing on both healthcare and the economy. In an ideal world, wounds 
would always heal rapidly and scar-free, but how could this goal be achieved? Skin 
tissue engineering (STE) explores the promising opportunities in this field, either 
alone or combined with traditional wound treatments. The main tasks of STE are to 
enhance the quality of healing and to reduce scarring (Wood, 2012). In addition, STE 
aims to introduce much needed help for the treatments of nonhealing wounds, as well 
as injuries such as large burns, when the possibilities for skin grafting are limited and 
substitutive material is needed to cover the damaged tissue (Mansbridge, 2008).  
 
  
Figure 4. Concept of tissue engineering. 
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To be accepted by healthcare professionals, a good STE therapy must be practical as 
well as cost- and time-effective. When designing therapy, one should understand the 
aetiology and pathophysiology of the wound; in other words, which mechanisms to 
inhibit and which to induce, what structures should be mimicked and what replaced. 
Another crucial point to grasp is that there is no single solution that would optimally 
suit all defects and all causes. 
  
In general, the cells that form the superficial epidermal protective layer are needed for 
a skin wound to heal. Equally important is the dermal component and the ECM, 
which can support epidermal cell proliferation, migration and differentiation 
(Böttcher-Haberzeth et al., 2010; Zhong et al., 2010). 
 
 2.3.1 Cell therapy 
The first question with cell therapy is always whether to use autologous or allogeneic 
cells. Both have their pros and cons. Autologous cells offer a more permanent 
solution with fewer worries of any rejection or disease transfer. On the other hand 
their availability and preparation time often limit their use. Allogeneic cells would 
potentially be available when needed, but their benefits are mainly limited to factors 
secreted by the cells. Legislation concerning cell therapy is very strict and even 
stricter when dealing with allogeneic or cultured cells (European Medicine Agency, 
human cell-based medicinal products, CHMP/410869/06). The problem with cultured 
cells is that culturing may cause mutations and thus the altered cells could cause 
cancer when transplanted back to the patient. This is especially dangerous in the case 
of autologous cultures, because they are not recognized as foreign. 
 
Keratinocyte transplantation is the best-known skin-related cell therapy. Since 1975, 
when Rheinwald and Green succeeded in cultivation and expansion of epidermal 
keratinocyte populations, cultured epithelial autografts (CEAs) have been used to treat 
burns throughout the world (Rheinwald & Green, 1975). Although a promising 
technique, it has struggled to gain acceptance and has never become a standard 
treatment. CEAs have many problems of which the time required for cell culturing is 
the most challenging (Carsin et al., 2000). It requires several weeks to expand the 
cells into a confluent sheet. It is also difficult to time the operations with the delivery 
of cultured cells (Wood et al., 2006). Other problems include poor adherence and high 
costs. In addition, CEAs are very fragile and difficult to handle upon transplantation 
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(Böttcher-Haberzeth et al., 2010; Chester et al., 2004).  
The problems with CEAs ushered in development of several other techniques and 
solutions for keratinocyte transplantation. Cultures have been harvested as 
preconfluent, in order to reduce the time required for a confluent sheet to form 
(Johnen et al., 2008). In this approach, cells can be transplanted as a suspension or a 
spray on the damaged tissue. Commonly, preconfluent cultures are combined with 
scaffolds. The most straightforward way is to culture cells on the scaffold and 
transplant this engineered structure on to the wound. Biological polymers, such as 
collagen (Horch et al., 2000) or fibrin (Ronfard et al., 1991), have been used as 
delivery vehicles for keratinocytes. In these studies, isolated keratinocytes have been 
plated on or inside the material and cultured for several days before transplantation 
(Bannasch et al., 2000). The cell spray approach has also been used in several 
countries. The benefits of this technique include rapid application and feasibility of 
treating large areas without need of a scaffold. By spraying the cells it is possible to 
treat areas up to 800 times larger than the area harvested. Another benefit is the ability 
to perform the entire procedure bedside in a very short period of time. The drawbacks 
are poor attachment and loss of cells due to mechanical pressure while spraying. In 
addition, the amount of cells must be large enough to obtain any meaningful effect 
(De Angelis et al., 2013; Fredriksson et al., 2008; Gerlach et al., 2011; Hartmann et 
al., 2007; Kirsner et al., 2012). Currently, there is one commercial product, ReCell®, 
on the market that utilizes this technique. The ReCell® kit includes all the tools 
needed for isolating keratinocytes from the skin. Thus, the procedure can be 
performed on-site in approximately 1 hour (Wood et al., 2012).  
 
In one study, Gravante et al. (2007) concluded that ReCell® is a feasible, simple and 
safe technique that gives results similar to those of STSG. However, it is best fitted 
for the treatment of smaller cosmetic skin conditions, such as vitiligo (Cervelli et al., 
2009). To treat large areas, such as burns or chronic wounds, up-scaling is essential. 
In a recent multicentre, double-blind, randomized, placebo-controlled trial, Kirsner et 
al. (2012) treated chronic leg ulcers by spraying human allogeneic fibroblasts and 
keratinocytes. The study concluded that chronic wounds could be healed by spraying 
cells, even without any additional TE. The trial also indicated that an optimum dose 
would behalf a million cells every 14 days. 
 
In addition to keratinocytes other cell types such as fibroblasts and mesenchymal stem 
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cells (MSCs) have been evaluated in the treatment of skin wounds (Boyce et al., 
2002; Guenou et al., 2009; Ramanauskaitė et al., 2010). MSC therapy especially, has 
been considered as a potential form of skin therapy. The great benefit with stem-cell 
treatment is that autologous cells would be abundantly available from different 
sources such as from bone marrow or adipose tissue. Allogeneic MSC products, such 
as Stemedyne™-MSC and Revascor®, are already available commercially to treat 
cardiovascular diseases. 
  
In addition to their capability of differentiation into skin cells, MSCs are believed to 
enhance dermal regeneration by several ways throughout the various stages of the 
wound-healing process (Salem & Thiemermann, 2010). In preclinical studies, MSC 
during the inflammation phase could modulate the immune response by inhibiting the 
recruitment, proliferation and biological activity of immune cells. In the wound 
environment, MSCs also secrete prostaglandins (PTGs), which favours regeneration 
(Jackson et al., 2012a). In the new-tissue formationphase, MSCs promote wound 
healing by secreting several GFs contributing to cell proliferation and angiogenesis. 
In addition, MSCs are believed to attenuate fibrosis (Jackson et al., 2012b). In the 
final stage of the healing process, MSCs can transdifferentiate into keratinocytes and 
fibroblasts and enhance re-epithelialization and production of new ECM. Of course, 
the big problem in dealing with stem cells is their uncontrolled differentiation and 
tumour risk (Semi et al., 2013). 
 
2.3.2 Bioengineered skin 
Engineering of a skin substitute has proven to be extremely challenging, due to the 
complex, multilayered, appendage-containing structure of skin. An ultimate goal of 
skingineering would be to succeed in building a dermoepidermal substitute that would 
vascularize rapidly, be biodegradable and support cell migration and proliferation. 
Equally as important, the matrix should be convenient to use as well as affordable 
(Pham et al., 2007; Wood, 2012). Materials such as collagen, fibrin and gelatin have 
been commonly used in skin bioengineering, both as dermal fillers as well as delivery 
vehicles for cells but do not fulfil all the abovementioned qualities (Bello et al., 2001; 
Metcalfe & Ferguson, 2007). 
  
So far, Apligraf® is the only commercially available Food and Drug Admistration 
(FDA)-approved, bilayered dermoepidermal skin substitute containing living cells. It 
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has both dermal and epidermal layers and is histologically similar to normal human 
skin. Its dermal layer contains type I bovine collagen and allogeneic fibroblasts 
whereas the epidermal layer is made of allogeneic keratinocytes. Both cell types are 
obtained from neonatal foreskin. Apligraf® is currently used in the treatment of 
chronic wounds, and some promising results have been reported, especially in the 
treatment of venous ulcers (Barber et al., 2008; Edmonds et al., 2009; Fivenson et al., 
2003).  
 
Dermagraft® is another living cell-containing skin substitute. It is a meshed 
polyglactin scaffold seeded with allogeneic human fibroblasts. The fibroblasts 
proliferate in the scaffold and secrete dermal collagen, GFs, matrix proteins and 
cytokines. During the process, the scaffold material is gradually degraded. 
Dermagraft® is used as a temporary or permanent cover in the treatment of burns and 
chronic wounds. Clinical studies have shown that Dermagraft® is as good as an 
allograft in terms of wound infection, wound exudate, wound closure, wound-healing 
time and graft take (Edmonds et al., 1997; Hansbrough et al., 1997; Harding et al., 
2013). 
 
There are several acellular dermal substitutes on the market, which combined with 
skin grafts, have given promising results (Iorio et al., 2012). Integra® is among the 
most generally used acellular dermal scaffolds. It contains two layers; the bottom 
layer is made of bovine tendon collagen cross-linked with glycosaminoglycans. The 
structure supports capillary and cellular ingrowth (Pandya et al., 1998). The upper 
part is a semipermeable silicon layer that prevents water-vapour loss and adds 
strength to the scaffold. The idea of Integra® artificial skin is to act as an off-the-shelf 
dermis that can be combined with either laboratory-grown keratinocytes or STSG. 
However, there are some problems such as poor graft take on the top of Integra®, as 
well as the expensive price. An additional challenge is the two-step procedure, which 
means that STSG or cells cannot be placed on the top of the matrix before granulation 
tissue has grown through the matrix (Hansen et al., 2001; Iorio et al., 2012). 
  
Matriderm® is another similar, cell-free dermal skin substitute. Its dermal component 
is composed of collagen and elastin, both of bovine origin. Matriderm® is also used 
as a two-step procedure together with STSG for the reconstruction of dermis in 
wound and burn surgery. Clinical trials have shown that in the treatment of burns, 
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Matriderm® promotes healing with satisfying aesthetic and functional results. Similar 
to the other materials, its indications are limited by its high costs (Böttcher-Haberzeth 
et al., 2010; Cervelli et al., 2011; Haslik et al., 2010; Keck et al., 2011). 
 
Although many artificial skin products have been developed, the market still lacks a 
cost-effective, single-step, dermoepidermal skin substitute. Commercially available 
artificial skin products, their origins and indications are presented in Table 2. 
 
2.3.3 Topical growth factor therapy 
GFs play important roles in the process of normal wound healing (Werner & Grose, 
2003). Thus, topical administration of GFs directly to the wound has been studied 
intensively as a potential regenerative treatment, especially for nonhealing wounds. 
Several GFs, EGF, PDGF, TGF-β, and FGF-7 (also called keratinocyte growth factor, 
KGF), have been considered as potential agents for therapy (Hardwicke et al., 2008; 
Mansbridge, 2008). However, there are only a few of FDA-approved products 
available for clinical use. Regranex gel ® contains human recombinant PDGFs and is 
produced, using recombinant deoxyribonucleic acid (DNA) technology (Wiemann et 
al., 1998). It promotes angiogenesis and accelerates wound healing in diabetic ulcers 
(Sibbald et al., 2003). Another product, called AutoloGelTM, contains autologous 
PDGFs derived from the patient’s own blood (Driver et al., 2006). In a randomized 
clinical trial, Carter et al. (2011) indicated that chronic wounds respond positively to 
AutoloGelTM treatment. 
 
There are some limitations related to GF therapy. First of all, it is by no means certain 
whether the application of a single GF efficiently enhances the healing process. Might 
a cocktail of various GFs function more effectively? On the other hand, the 
production of recombinant GFs is very laborious and expensive. Another serious 
concern is that proteolytic enzymes in the wound exudate may lyse topically applied 
proteins. Thus, the amount of GFs administrated to the wound must be large to obtain 
any effect. For example, Regranex® treatment requires a dose of 100 µg/cm2 every 
other day (Niezgoda et al., 2005).  
2.3.4 Gene therapy 
To address the problems of GF therapy, genetic approaches have been in focus. In 
gene therapy, foreign DNA is delivered into the host cells. As a wound-healing 
therapy the aim would be to stimulate and enhance the production of proteins, such as 
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GFs, secreted by the cells (Eming et al., 2007). There are two ways to deliver genes 
into target tissue, either in vivo or ex vivo. Ex vivo techniques are more expensive, 
laborious and time-consuming. First, the target cells are isolated from tissue and 
cultured in vitro; subsequently they are transfected and finally transplanted back into 
a recipient. In vivo techniques, in which genes are introduced directly to the target 
tissue, are more straightforward and more reasonable in price. In both approaches, 
transfection can be achieved using viral or nonviral genes. Viral gene transfer relies 
on the natural ability of viruses to penetrate into cells and express their genes in hosts. 
The most commonly used viruses for transfection are retro- and adenoviruses. Viral 
gene transfer in to aid cutaneous wound healing has been studied in several animal 
models with some promising results (Jeschke et al., 2005; Rosenthal et al., 1997; Vogt 
et al., 1994). Unfortunately, the biggest problem with this approach seems to be 
inflammation and infection risk caused by the virus, which can lead to impaired 
healing instead (Vogel, 2000). Nonviral gene transfer includes naked DNA 
transfection and liposomal transfection. Nonviral techniques are more simple and 
inexpensive. In addition there are no inflammation or infection risks. However, these 
methods are nonspecific and vary in the level of gene expression (Branski et al., 
2007). So far, there are only a few commercial gene therapy products approved for 
clinical use in humans. Gendicine™ and Advexin™ are products based on p53 
expression and indicated for treating cancer (Gabrilovich, 2006; Peng, 2005). 
Additionally, the adeno-associated viral vectors OncorineTM and CereproTM, also for 
cancer care, are emerging in the markets (Räty et al., 2008). 
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Table 2. Examples of commercial skin substitutes. 
  
Product Type of 
substitute 
Composition Indication 
CellSpray® epidermal Cultured epithelial autograft 
suspension 
For treatment of superficial burns. 
Can be used together with a dermal 
product to treat deep dermal burns 
 
Epicel® epidermal Cultured epidermal autograft. 
Autologous keratinocytes grown 
from patient skin biopsy. 
For treatment of deep dermal and 
full-thickness wounds, alone or in 
conjunction with STSG. 
 
MySkin® epidermal Cultured epidermal autograft. 
Autologous keratinocytes grown 
from patient skin biopsy. 
 
For the treatment of burns, ulcers 
and other nonhealing wounds. 
ReCell® epidermal Autologous epidermal cell 
suspension 
For treatment of burns, scars, 
hypopigmentation and vitiligo 
 
Alloderm® dermal Processed human allograft with 
acellular dermal matrix and 
intact basement membrane 
For the treatment of full-thickness 
burns and use in plastic and oral 
surgery 
 
Dermagraft® dermal Bioabsorbable polyglactin mesh 
scaffold seeded with human 
allogeneic neonatal fibroblasts 
 
For treatment of foot ulcers in 
diabetic patients 
Integra® dermal Silicone, cross-linked bovine 
tendon, collagen type I and 
shark glycosaminoglycan 
For treatment of burns and full-
thickness wounds in conjunction 
with STSG 
 
Matriderm® dermal Bovine collagen type I, II, V and 
elastin 
For treatment of burns and full-
thickness wounds in conjunction 
with STSG 
 
EZ-Derm® dermal Porcine-derived xenograft in 
which collagen is cross-linked 
with aldehyde 
 
For treatment of partial-thickness 
wounds 
Apligraft® dermoepidermal Human allogeneic neonatal 
keratinocytes on neonatal 
fibroblasts containing bovine 
collagen type I 
 
For treatment of burns and partial- 
and full-thickness ulcers 
OrCel® dermoepidermal Human allogeneic neonatal 
keratinocytes on bovine collagen 
sponge containing human 
allogeneic neonatal fibroblasts 
For treatment of burns and partial- 
and full-thickness ulcers 
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2.4 Translational wound-healing research 
 
The biggest problems in clinical wound-healing research are the lack of 
corresponding control wounds and the difficulty in monitoring the healing in an 
objective manner. In addition, ethical questions arise when testing a new product or 
harvesting tissue samples from humans. Thus, preclinical studies with animals as well 
as in vitro studies in the laboratory are crucial to investigating the molecular-level 
mechanisms behind the wound-healing process. In vitro wound-healing models are 
essential tools for studying in-depth responses selectively in a given cell population, 
in terms of behaviour (such as differentiation capacity or barrier function), responses 
to stimuli (such as GFs) or cell-cell interactions. Animal models are fundamental in 
the development, efficacy and safety testing of new therapies or products. Moreover, 
they make it possible to mimic clinical problems in a controlled manner. 
  
Several animals, such as mice, rats and rabbits, have been used in wound-healing 
research over the years (Arai et al., 2012; Benavides et al., 2009; Dorsett-Martin et 
al., 2004). However, preclinically the pig is the best animal to study and test therapies 
prior to adoption for clinical use. Porcine skin is very similar both in structure and 
function to human skin (Montagna & Yun, 1964). Both have an avascular epidermis 
that is multilayered and varies in thickness in different body parts. Porcine dermis 
resembles human dermis being divided into an upper papillary layer and lower 
reticular layer. In both human skin and pigskin, the ratio of the epidermis to dermis is 
similar. The vascular organization is also alike and, more importantly, wounds heal 
through epithelialization as in humans. The practical advantages compared with other 
animals are an appropriate size and less hairy body. Some differences do exist, 
however, such as that pigskin does not contain eccrine glands and the apocrine glands 
are different (Vardaxis et al., 1997).  
 
2.5 Gene expression profiling in wound-healing research 
 
Although skin wound healing has been studied for decades, the molecular 
mechanisms behind the process are still not completely clear and most of the 
molecular-level understanding has been derived from various animal models. 
Fortunately, RNA- and DNA-based techniques have enabled molecular-level 
information to be obtained even from a small sample of tissue. Since these methods 
 
require only a small amount of patient skin, they make it possible to study wound 
healing directly in humans. With techniques such as polymerase chain reaction (PCR) 
and microarray, it is possible to investigate how the expression of different genes is 
altered in skin during trauma or disease. More importantly, these techniques offer an 
unbiased approach to the observation of healing. However, it should be recalled that 
these techniques may have limitations concerning heterogeneous cell types in a tissue 
sample. 
 
2.5.1 Polymerase chain reaction 
The PCR is a biochemical technology in which a specific region of DNA is amplified 
using a PCR machine in vitro. Currently, several variations of the basic PCR exist, 
including real-time PCR, reverse transcription PCR, nested PCR, quantitative PCR 
and assembly PCR (Sze, 2004). The PCR technique can be used for several 
applications, such as identification of genetic fingerprints, diagnosis of hereditary and 
infectious diseases, and cloning the DNA for sequencing. In wound-healing research, 
it is used to recognize gene transcriptional activity during repair. There are even 
specific wound-healing PCR kits on the market, which make it possible to 
simultaneously follow several particular wound-healing-targeted genes (Bartlett & 
Stirling, 2003). The role of GFs in wound repair has been emphasized and thus their 
expression is studied widely using PCR (Werner & Grose, 2003; Kondo & Ishida 
2010). A good example of PCR in clinical wound-healing research is a study by 
Conway et al. (2007). They investigated the role of HGF with PCR in human wound 
healing by obtaining skin biopsies from chronic wound tissue, acute wound tissue and 
normal skin. Their study showed that both HGF and its receptor c-Met are expressed 
differently in acute and chronic wounds (Conway et al., 2007). 
  
2.5.2 Microarray 
Microarrays are another much used procedure for various gene expression studies. 
Microarray chips are composed of microscopic DNA spots, called probes that contain 
picomole amounts of a specific DNA sequence. The key method behind microarrays 
is hydridization between two DNA strands; the probes detect the target DNA that is 
complementary to its sequence. The difference between a microarray and PCR is that 
with this technology it is possible to examine expression of all genes in the genome at 
the same time. 
  
 
So far, the utilization of microarrays in wound-healing research has been modest. 
However, some interesting studies do exist. Smiley et al. (2005) used microarrays to 
better understand the molecular differences between cultured skin substitutes and 
native skin. Their gene expression analysis revealed that entire clusters of genes were 
either up- or down-regulated upon combination of fibroblasts and keratinocytes in 
cultured skin grafts. Furthermore, several categories of genes were overexpressed in 
cultured skin substitutes compared with native skin, including genes associated with 
hyperproliferative skin or activated keratinocytes (Smiley et al., 2005). In another 
study, Chen et al. (2010) investigated why oral mucosal wounds heal more rapidly 
and with reduced scar formation than cutaneous wounds. They obtained biopsies of 
both oral mucosal and skin wounds and used microarrays to compare the 
transcriptomes in order to find critical differences in the healing response at these two 
sites. Their results demonstrated dramatically different reactions to injury between 
skin and mucosal wounds. In a study by Greco et al. (2010), the gene expression 
profiles of thermally injured human skin were observed with microarrays. For the 
analysis, skin samples were collected from 45 burn patients and the transcriptomes 
were compared with those from 15 control patients. Greco et al. found that the 
expression of several hundreds of genes was altered significantly between groups, 
including many calcium-binding proteins, cytokeratins, and chemokines. In one study, 
Deonarine et al. (2007) investigated gene expression changes in skin wounds by 
collecting punch biopsies before and after wounding from basal-cell carcinoma 
patients. They concluded that the initial response to a cutaneous wound induces 
transcriptional activation of proinflammatory stimuli that may alert the host defence. 
It would be advantageous to be able to adopt all existing and future microarray data 
for clinical use, as has already happened, e.g. in cancer biology, using expression 
signatures as diagnostic and prognostic tools (Quackenbush 2006; van de Vijver et al., 
2002).  
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3. Aims of the study 
 
There is clearly a clinical need for effective skin-healing treatments for the increasing 
incidence of chronic wounds and still inadequate solutions for major skin-loss trauma, 
especially burns. The main goal of this thesis was to use the relatively new technology 
of transcriptome array analysis, to study wound-healing trajectories with a genome-
wide ‘resolution’ of gene expression changes underlying the physiological healing 
response over time. The main hypothesis was that transcriptome array analysis will 
allow the identification and confirmation of previously established molecular 
regulatory events, and identify new events, which may suggest or extend therapeutic 
strategies 
 
The objectives of the individual studies were to: 
 
I clarify what happens to gene expression in the acute, inflammation and 
proliferation phases of superficial cutaneous wound healing, to identify the 
genes that are activated over time, and to organize the genes into groups 
according to the similar patterns observed in their expression profiles. 
 
II clarify the potential of the approach in a real clinical context, using NPWT as 
a model experiment.   
 
III clarify the differences in gene expression between the intact skin and the 
already re-epithelialized donor site wound. 
 
IV to pilot the introduction of a newly available type of collagen, which 
exemplifies the possible use of advanced biomaterial/cell therapy for skin 
reconstruction. 
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4. Materials and methods 
 
4.1 Microarray studies 
4.1.1 Patients and sample collection 
 
Human skin tissue samples were obtained from the Burn Centre of Helsinki 
University Hospital, Helsinki, Finland and from the Department of Surgery of 
Satakunta Central Hospital, Pori, Finland. All samples were taken with a 3-mm 
diameter biopsy punch from patients scheduled to undergo STSG. Skin graft 
harvesting was carried out with a compressed air-driven dermatome (Zimmer®, 
Zimmer Holdings Inc., Warsaw, IN, USA). The graft sizes ranged from 10 to 25 cm x 
7.5 cm with a fixed thickness of 10/1000 inches (0.25 mm). The donor site wounds 
were covered with OpSite® polyurethane dressing (Smith & Nephew plc, London, 
UK). The wounds were photographed after the graft harvesting and during dressing 
changes. Wounds with early signs of clinical infection (enhanced secretion, pain, and 
positive swap culture) were excluded from the study. The patient exclusion criteria 
included diabetes, skin disease, cortisone treatment, immune suppression, 
anticoagulation, bleeding disorder, and unstable heart disease. Figure 5 illustrates 
sample collection in various studies. 
 
Study I 
Three to four samples of each patient were collected from four different time points. 
The first sample was taken from the intact skin immediately before STSG from the 
area to be wounded. The second was obtained from the acute wound, immediately 
after STSG. The third and fourth samples were biopsied from the same wound 
through the polyurethane dressing on the 3rd and 7th PODs (Figure 5). A total of 40 
biopsies were collected from 12 patients (five from Helsinki, three from Pori), out of 
which 25 biopsies from eight patients met the RNA yield and quality criteria for 
inclusion in the study. All patients were healthy males between 20 and 75 years of 
age.  
 
Study II 
Twelve biopsies from two time points were collected from six patients. The first 
sample was taken from the intact skin immediately before STSG from the area to be 
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wounded, and the second from the wound through the dressing on the 7th POD. The 
patients were randomly selected by cointoss to receive either NPWT or control 
therapy. For this study, four patients received NPWT and two were controls. Negative 
pressure at 100 mmHg was continuously applied to the NPWT patients from the 1st 
POD until the 7th (Figure 5). Two porous Polymem® Wic® (3×3 inches, Ferris Mfg. 
Corp., Burr Ridge, IL, USA) dressings were placed at the donor site. The suction tube 
was placed between these porous dressings. An OpSite® polyurethane dressing (Smith 
& Nephew) was then placed so as to cover the entire donor site wound. The dressings 
were changed on the 3rd and 7th PODs. Control therapy consisted of a wound dressing 
similar to that used for the NPWT patients, but the suction tubing from the wound 
was closed and no negative pressure was applied.  
 
In addition, wound exudates were collected from all patients and analysed for 
leukocyte, erythrocyte and haemoglobin concentrations, as well as for volume. 
Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software Inc., 
San Diego, CA, USA). The NPWT samples were collected from the canister 
containing the evacuated fluid, and control samples were obtained by needle 
aspiration under the dressing. Exudates were obtained on the 1st, 2nd and 3rd PODs. 
The patients participating for this study were male and female between 20 and 75 
years of age.  
 
Study III 
Three samples were collected from four patients. As in the previous studies the first 
was obtained from the intact skin before STSG. The latter two were taken on the 14th 
and 21st PODs (Figure 5). All patients were male burn patients between 20 and 75 
years of age.  
 
4.1.2 Sample processing 
Tissue homogenization and RNA isolation 
The human skin tissue biopsies obtained were immediately immersed in RNAlater® 
buffer according to the manufacturer’s instructions (Qiagen GmbH, Hilden, 
Germany). They were then incubated at +4 °C for 1 day, and subsequently stored at -
80 °C until RNA isolation. 
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Before isolation of total RNA, the samples were homogenized, using the Precellys 24-
tissue homogenizer with a Cryolys temperature controller unit (Bertin Technologies 
SA, Montigny-le-Bretonneux, France). The frozen samples were placed in the hard 
tissue-homogenizing tubes (Bertin Technologies) with small ceramic beads and 350 
µl of RLT lysis buffer (Qiagen). The biopsies were processed 3 x 23 s at 6000 
revolutions per minute (rpm). The temperatures ranged between -5 °C and +10 °C 
during the homogenization.  
 
Thereafter, the total RNA was extracted from the homogenized tissue samples with an 
RNeasy® Mini Kit (Qiagen), according to the manufacturer’s protocol. The RNA 
quality was measured using an Agilent 2100 bioanalyser (Agilent Technologies Inc., 
Palo Alto, CA, USA) to ensure RNA integrity. After the RNA isolation, the RNA 
integrity was measured for each sample to ensure that the RNA quality was adequate 
for the microarray process. 
 
Histology 
For histology, the tissue samples were placed in formalin and fixed for 7 days. 
Thereafter, the samples were transferred to 70% ethanol for storage until paraffin 
embedding. After embedding in paraffin blocks, 4-µm-thick sections were cut, using a 
microtome. The sections were stained with haematoxylin and eosin (H&E). 
 
Microarray 
The purified RNA was synthesized into double-stranded complementary DNA 
(cDNA) with a Superscript double-stranded cDNA synthesis kit (Affymetrix Inc., 
Santa Clara, CA). A Bioarray High Yield RNA transcript labeling kit (Affymetrix) 
was then used to synthesize the complementary RNA (cRNA). The cDNA and cRNA 
products were purified with a GeneChip sample cleanup module (Affymetrix). The 
cRNA products were then used for the fragmentation reaction and hybridized into the 
Affymetrix Human Genome U133 Plus 2.0 GeneChip Array (Affymetrix). After 16 
hours, the chips were washed and stained with a GeneChip Fluidics Station 450 
(Affymetrix), followed by chip scanning with a GeneChip Scanner 3000 7G 
(Affymetrix). In addition to the Affymetrix GeneChip array, Illumina Human HT-12 
GeneChips (Illumina Inc., San Diego, CA, USA) were also used. In the first study, 
parallel experiments were done, using the Affymatrix as validation method, while the 
third study was executed, using only the Illumina Human HT-12 GeneChip. All 
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microarray data are Minimum Information About a Microarray Experiment-compliant 
(MIAME) (Brazma et al., 2001) and were deposited in the National Centre for 
Biotechnology Information’s (NCBI) Gene Expression Omnibus with accession 
numbers GSE28914 and GSE33169 and can be accessed at 
http://www.ncbi.nlm.nih.gov/geo. 
 
Quantitative real-time PCR 
Before PCR, the total RNA was translated into cDNA using the RT2 First Strand Kit 
(Qiagen). The PCR was used as a data validation method in the first study and was 
executed with the Human Wound Healing PCR 96-well array (Qiagen), according to 
the manufacturer’s protocol using the CFX96 instrument (Bio-Rad Laboratories Inc., 
Hercules, CA, USA). The data were analysed using the PCR Array Data Analysis 
Web Portal (http://www.SABiosciences.com/pcrarraydataanalysis.php) (Qiagen).  
 
Microarray data analysis 
The Affymetrix and Illumina microarray data were analysed in a similar manner. The 
GeneChip signal intensity data were uploaded to GeneSpring GX software, version 
11.0.1 (Agilent Technologies) and normalized to the median. Experimental grouping 
was then performed according to therapy and time point. The data were then 
interpreted to pool together the samples of the patients from each group. Finally, the 
data were presented as gene expression fold changes between groups. 
 
The data were preprocessed with robust multiarray analysis (Irizarry et al., 2003) and 
median expression values were derived. Further statistical analyses were done, using 
the limma, BioMart and qvalue packages of the Bioconductor Project (Durinck et al., 
2005; Gentleman et al., 2004; Smyth, 2004; Storey & Tibshinari, 2003). At first, 
Affymetrix type of probe set names given in the chip were converted to EnsEMBL 
gene names using BioMart (Durinck et al., 2005). Those probe sets matching multiple 
EnsEMBL entries and probe sets not matching any EnsEMBL entry were removed 
from the data. The probe sets matching the same EnsEMBL entry were averaged into 
a single expression estimate for that EnsEMBL entry. The significance of the 
differential expression was assessed, using the empirical Bayes-moderated paired t-
statistics followed by p-value adjustment with the Storey's Q-value approach (Smyth, 
2004; Storey & Tibshinari, 2003). Pairing of the patient samples was done by 
allowing patient-pair effects in the linear model. The arrays were quality-weighted 
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before statistical testing (Ritchie et al., 2006). Genes with Q-value-corrected p-values 
≤ 0.05 were considered as significantly differentially expressed. 
 
 
Figure 5. Schematics of the studies I - III. 
 
 
4.2 Transplantation of skin cells inside collagen gel 
 
4.2.1 Primary cell isolation and culture 
A tissue sample was obtained from the dorsal skin of a landrace pig under general 
anaesthesia. The skin sample obtained was carefully washed with antibiotics 
containing phosphate-buffered saline (PBS), the subcutaneous fat was removed and 
the sample was minced. To separate the epidermis and dermis, the tissue samples 
were incubated overnight in PBS diluted with 2U/ml dispase (Dispase®, Roche 
Diagnostics Deutschland GmbH, Mannheim, Germany). After incubation, the 
epidermis was peeled off from the dermis, using needles. 
 
The primary keratinocytes were isolated from the epidermis by further (about 5 min) 
incubation in 0.1% trypsin-PBS (Sigma-Aldrich Corp., St. Louis, MO, USA) at +37 
°C. After incubation, the samples were pipetted strongly to the detach cells from the 
epidermis. The gained single-cell suspension obtained was then seeded on a rat-tail 
collagen-I (Sigma-Aldrich) coated cell culture dish and grown in defined keratinocyte 
serum-free medium (K-SFM; Invitrogen™, Life Technologies Corp., Carlsbad, CA, 
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USA) supplied with growth supplement (Life Technologies) and 1% penicillin-
streptomycin (Life Technologies) 
 
Primary fibroblasts where obtained from the remaining pieces of dermis. The samples 
were incubated in collagenase IV (1 mg/ml; Worthington Biochemical Corp., 
Lakewood, NJ, USA) and 0.1% trypsin (Sigma-Aldrich) solution (2 x 1 hour, +37°C). 
Thereafter, the cells were seeded in a coated cell culture dish and grown in Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM / F-12) supplied with 10% 
bovine serum and 1% penicillin-streptomycin (all from Life Technologies). 
 
4.2.2 Primary cell-containing collagen gel preparation 
The rhCol-III was used as a carrier material for cells (FibroGen Inc, San Francisco, 
CA, USA). To develop a gel, the pH was adjusted from the initial 2 to 7.2 by adding 
sodium phosphate (Na3PO4) in a 9:1 ratio. Thereafter, the rhCol-III solution was 
transferred to 1ml syringes. To strengthen the gel, the concentration of the rhCol-III 
was fixed by centrifuging the syringes at 5000 g (3 x 5 min). After each 
centrifugation, the supernatant was discarded and 1 ml new rhCol-III solution was 
added to the syringe to gradually increase the gel volume. 
 
Next, cells from the primary cultures were detached from the culture dishes, using 
trypsin (Sigma-Aldrich), and pipetted on the top of the syringe. Two types of syringes 
were prepared: 1) keratinocyte syringes (containing 0.5 x 106 keratinocytes) and 2) 
keratinocyte-fibroblast syringes (containing 0.25 x 106 of both cell types) (Figure 6 
A). The cells were mixed inside the gel by centrifugation (350 g, 5 min). In coculture 
syringes, the fibroblasts were added first. In addition, acellular syringes, containing 
only rhCol-III, were prepared for controls. All syringes were then placed in the 
incubator (37 °C, 5% CO2) and kept there overnight prior to application (Figure 6 B).  
 
A confocal microscope (Leica Microsystems AG, Wetzlar, Germany) was used to 
ensure cell viability inside the gel. The cells were stained before mixing them inside 
the gel. CellTracker (Invitrogen) was used to stain the cytoplasm and DRAQ5 
(Axxora LLC, San Diego, CA, USA) to stain the nuclei. The syringes were prepared 
and after the overnight incubation, the gel was injected onto a microscope slide. A 
confocal microscope was executed using a Leica TCS SP2 acoustic optical beam 
splitter (AOBS) system with a argon 488-nm or diode-pumped solid-state laser 
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(DPSS) 561-nm with excitation lines and an HCX PL APO CS 63 x/1.40 NA or 40 
x/1.25 NA oil-immersion objective. The image stacks were collected through the 
sample, using sequential scanning and a standardized 120-nm z-sampling density. 
 
Figure 6. Concept of study IV. 
 
4.2.3 Full-thickness wounds and therapy application 
Two pathogen-free 2-month-old domestic landrace female pigs were anaesthetized, 
using an intramuscular injection of ketamine (4 - 6 mg/kg) and medetomidine 
(0.5 mg/kg). Anaesthesia was continued with intravenous (i.v.) infusion of propofol (4 
- 10 mg-1 kg-1 h-1).  
 
Prior to wounding the back of the pig was shaved, washed thoroughly and cleaned 
with 0.5% chlorhexidine. Thereafter, 14 identical deep dermal wounds were made on 
the back of each pig, using an 8 mm biopsy punch, seven wounds on each side of the 
spine.  
 
Therapy was applied by injecting the prepared syringes into the wounds: keratinocyte 
syringes (n = 8), keratinocyte-fibroblast syringes (n = 8), acellullar (n = 8). In 
addition, empty untreated wounds (n = 4) were used as an additional control for 
treated wounds. For each wound the treatment was randomized. After the application, 
the wounds were covered with an OpSite® polyurethane dressing (Smith & Nephew) 
 
and healing was followed up for 5 days. On the 5th POD, the wounds were excised 
with ample margins and placed in 10% formaldehyde solution for fixation. 
4.2.4 Histological analysis 
After fixation, the wound samples were trimmed, embedded in paraffin and cut into 
4µm-thick sections. To observe the development of granulation tissue and wound 
healing, the sections were stained with H&E, then viewed under a microscope and 
photographed (Leica IM500 and Leica QWIN software; Leica Microsystems AG, 
Heerbrugg, Switzerland). The amount of granulation tissue was measured from the 
bottom of the wound bed, and the wound healing was measured as the reduction in 
the empty area per wound section. To assure objectivity, the analyses were performed 
in blind fashion. 
 
Paraffin sections were also used for immunohistochemical analysis. The sections were 
stained with mouse antihuman pancytokeratin antibody (diluted 1:40; EMD Millipore 
Corp., Billerica, MA, USA) to identify keratinocytes in the wound bed. DAB (3,3-
diaminobenzidine) was used as the chromogenic substrate for the secondary antibody-
conjugated horseradish peroxidase (HRP) for visualization of pancytokeratin-positive 
cells. Positive cells from the stained sections were identified using ImageJ software 
(ImageJ, National Institutes of Health; (NIH); http://rsb.info.nih.gov/ij). 
 
Sirius Red staining was performed to calculate the amount of collagen in the wound 
bed. The previously stained sections were deparaffinized followed by a 1-h incubation 
in the dark with Sirius Red dye in saturated aqueous picric acid (1 mg/ml). After the 
incubation, the sections were washed three times in running tap water. The sections 
were then dehydrated in ethanol and xylene before being permanently mounted in 
DPX (Leica Microsystems). The total collagen content was calculated as the 
percentage of the Sirius Red-stained positive area from the total wound area in 
scanned images of the stained tissue sections with ImageJ software. 
 
4.2.5 Statistical analysis 
GraphPad Prism 4.0 (GraphPad Software) was used to analyse the data. Statistical 
analyses were performed, using Student's t-test (two-tailed). A p-value  <  0.05 was 
considered statistically significant.  
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4.3 Ethics 
 
In the microarray study, the protocols were approved by the Operative Ethics 
Committees of the Pirkanmaa Hospital District (approval number R09087, studies I 
and II) and the Hospital District of Helsinki and Uusimaa (DNRO 101/13/03/02/11, 
study III). All samples were obtained in accordance with the Declaration of Helsinki 
Principles and all patients gave their informed consent on participation in the studies.  
 
In the study IV, all animals were maintained and treated in accordance with the 
Principles of Laboratory Animal Care (NIH Publication No. 8623, revised 1985). The 
study was approved by the Provincial State Office of Southern Finland (ESLH-2009-
03831/Ym-23). 
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5. Results 
 
5.1 Donor site wound healing 
 
The purpose of the first three studies was to map the gene expression changes 
occurring during the various stages of human superficial cutaneous wound healing. 
Standard depth, clean and consistently healing donor site wounds were used as 
models for the studies. Biopsies were collected over time to represent various steps of 
the healing process. The first biopsy was obtained before wounding from the intact 
skin, and the following biopsies, respectively, from the wound in the acute phase, on 
the 3rd, 7th, 14th, and 21st PODs. In addition, the interest was to see how the effect of a 
clinical wound therapy would be reflected in terms of gene expression changes. For 
this purpose, we used NPWT, which also served as an example.  
 
The behaviour of gene expression at the transcriptional level was investigated by 
comparing their messenger RNA (mRNA) levels at different time points. Finally, the 
data were presented as gene expression fold-changes between time points. Overall, 
clear changes in expression were manifested in thousands of genes, with the biggest 
changes being in the order of several hundredfold. The inter-individual variation in 
gene expression profiles between patients was very low, although the patients’ ages 
and general conditions varied.  In all studies the cut-off fold-change for a significant 
gene expression change was ≥ 2.0. Moreover, all the expression changes presented in 
the following chapters are statistically significant (p-value < 0.05). 
 
In addition, one must keep in mind that in all comparisons with intact skin, a negative 
fold-change of a gene can be due to removal of the cells expressing it, while a positive 
fold-change of another gene can be due to enrichment of cells expressing that gene in 
the tissue sample. 
 
5.1.2 Acute wounding  
What happens to the skin at the molecular level after wounding?  
This was studied by comparing the acute wound with the intact skin. In all, a 
statistically significant alteration in expression was observed for 8305 different genes 
(Figure 7). The genes most increased in expression (approx. fivefold) were KRT-
associated proteins (KRTAPs). The most decreased ones were the CE proteins-
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encoding genes, such as LCE 1 genes, sciellin (SCEL), envoplakin (EVPL), FLG, and 
LOR. Many genes of the keratin family (such as KRT1, KRT2, KRT23, KRT31 and 
KRT80) decrease, suggesting that the cells expressing them are removed in STSG. 
The most dominant gene in this respect was KRT2. It decreased in expression 430 
times against intact skin. Interestingly, the genes next on the list, such as IL-37 and 
secreted lymphocyte antigen 6 complex/plasminogen activator urokinase receptor 
domain-containing 1 (SLURP1), decreased only 20 - 50 fold, suggesting that these 
genes are significantly, albeit less strongly than the KRTs, expressed in the epidermis. 
  
5.1.3 Inflammation  
Which are the genes most dominant during the inflammation phase of wound healing?  
Gene expression in the inflammation phase was studied by comparing the samples 
collected on the 3rd POD with the acute wound samples. The inflammatory profile is 
characterized by high expression of ILs (such as IL-8), chemokine ligands, and 
receptors (such as chemokine (C-C motif) ligand 18 (CCL18), chemokine (C-X-C 
motif) ligand 5 (CXCL5), and C-X-C chemokine receptor type 4 (CXCR4)) as well as 
several leukocyte cell-surface antigens (such as cluster of differentiation 86 (CD86) 
and CD163). Additionally AMPs were very well presented. Genes, such as S100A7A 
and PI3 were among the most increased genes in this comparison. Overall, the 
expression of 10194 genes was altered in this comparison. 
 
Figure 7. Number of genes that are altered in expression during the wound-healing 
cascade in comparison to intact skin. The curve above the X-axis decribes genes 
whose expression increased and the curve below genes whose expression decreased. 
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5.1.4 New-tissue formation 
 
How are new-tissue formation and re-epithelialization reflected in gene expression?  
To provide an insight to genes associated with new-tissue formation, the 3rd and 7th 
POD samples were compared with the acute wound. The expression of 12068 and 
12275 genes changed respectively. Moreover, the 7th POD gene profile versus the 3rd 
POD profile was used to characterize the re-epithelialization phase. 
 
The gene family most visible, in comparing the gene profiles of both the 3rd and 7th 
POD with acute the wound profile, was the MMP family. The MMPs with the highest 
expression were MMP1, MMP3 and MMP10. Overall, in comparing the 3rd and 7th 
POD, with the acute wound, the genes with the highest expressional increase and thus 
closely associated with resurfacing overall were CCL18, IL8, MMP1, PI3, serpin 
peptidase inhibitor, clade B (ovalbumin), member 3 (SERPINB3), SERPINB4, 
secreted phosphoprotein 1 (SPP1), SPRR3 and S100A7A.  
 
Histologically some epithelial recovery was already visible on the 3rd POD but by the 
7th POD, the wound was almost fully covered with new epithelium and a thin CE. 
Thus, the re-epithelialization phase was explicitly described in comparison between 
the 7th and 3rd POD samples. The expression of several KRTs (such as KRT1, KRT4, 
KRT10, KRT13, KRT78 and KRT80) was higher. Remarkably, these include those 
KRTs (KRT1, KRT10, KRT78 and KRT80) that were removed by STSG in acute 
epithelial wounding. The development of a new CE was also evident by higher 
expression of many major CE components (such as FLG, LCE2B, LCE3D, LOR, 
SPRR1A and SPRR3). 
  
5.1.5 Tissue remodelling 
How close is the gene expression profile of skin in the remodelling phase to that of 
intact skin?  
The samples obtained on the 14th and 21st PODs were compared with the intact skin. 
At this phase of healing, the number of genes that are altered on expression decreases. 
The gene expression transcriptome slowly moves towards that of intact skin.  
 
In all, 2632 genes expression changes at 14 days after STSG in comparison to the 
intact skin and only 1610 by 21 days (Figure 7). In addition, the expression changes 
were more moderate than those in the earlier stages of healing. Overall, the gene most 
altered was KRT2 with a negative fold-change of almost 200 on the 14th POD, 
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compared with the intact skin. The profiles at both time points were very similar, with 
AMPs being the genes most increased (such as S100A7A) and KRTs and CE-
encoding genes being the most visible group of decreasing genes.  
 
The data reveal important roles for distinct control mechanisms that decrease the 
inflammatory process and promote epidermal maturation. Some of the key processes 
are associated with lymphocyte chemotaxis, iron homeostasis, shift in cytokine and 
chemokine profiles, as well as retinoic acid and lipid metabolism. 
 
5.1.5 Effect of NPWT on donor site wound healing 
Can we see the impact of a therapy at the gene expression level of wound healing?  
On the 7th POD patients receiving NPWT were compared with those not receiving 
NPWT. By this time point, the treated patients had been receiving the therapy 
continuously for 6 days. 
 
The results indicate that clear and statistically significant distinctions were present in 
the comparison data. Many genes that increase in the NPWT-treated patients were 
associated with cell proliferation and inflammation. The gene most increased was 
IL24, with a 10-fold difference between groups and the second in order was 
prostaglandin-endoperoxide synthase 2 (PTGS2) with an 8-fold induction. In addition, 
several other ILs and their receptors (such as IL1RL1, IL8, IL1A, and IL13RA2) were 
among the genes most increased as well as many MMPs (such as MMP3 and 
MMP10). 
 
The most interesting finding was that the genes most decreased were CE genes, all of 
which encode proteins of the SC. The gene most increased was FLG, with a fold-
change difference of 27. Other major CE components, such as FLG2, LOR, LCE1 and 
SLURP1 were all decreased. Another apparent group of decreased genes were the 
KRTs. Decrease in five different KRTs, all associated with keratinocyte 
differentiation (KRT1, KRT2, KRT10, KRT13 and KRT15) was evident. These 
findings suggest that the effect of NPWT is specifically targeted to inhibition of 
maturation of the epidermal layer. Thus, the differentiation-associated homeostasis of 
the epidermis may be delayed when NPWT is used. 
 
In addition, the wound exudate compositions were examined in both the NPWT and 
control patients. The exudates were collected from 11 patients for measurement of 
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leukocyte, erythrocyte and haemoglobin concentrations. The exudate volumes were 
also measured. The number of leukocytes on the 3rd POD was significantly smaller in 
exudates from wounds treated with NPWT (NPWT vs. control, p < 0.05). The number 
of erythrocytes in the NPWT wounds was smaller on the 1st POD, but clearly larger 
on the 2nd and 3rd PODs. The exudate volume was significantly (p < 0.05) larger in the 
NPWT wounds, suggesting that the NPWT was effectively administered. 
 
5.1.6 Gene expression data validation 
To validate the microarray gene expression data, some of the samples (eight biopsies 
from three patients) were analysed on two platforms (Affymetrix and Illumina), 
differing in array technology. The Affymetrix and Illumina arrays are based on 
completely different techniques and can thus be considered as separate platforms for 
the evaluation of gene expression. They differ in oligonucleotide physical attachment, 
probe selection and assay principle.  
 
The gene expression data from both microarrays were compared with the 
corresponding data of the same samples. Of the top 100 genes identified as increased 
on the Affymetrix platform, 97%, 98% and 100% were identified as increased on the 
Illumina in the acute phase and on the 3rd and 7th PODs, respectively. Similarly, 96%, 
99% and 98% of the decreased genes on the Affymetrix were identified as decreased 
on the Illumina (Table 3). 
 
To strengthen the validation, a quantitative real-time PCR array (Qiagen) was 
performed on one patient’s intact skin sample and 7th POD sample. This commercial 
PCR array provides gene expression profiles of 84 genes associated with the wound-
healing response. These genes expression alterations between the 7th POD and the 
intact skin were presented as fold-change differences similar to those in the 
microarray analysis. The results from the PCR arrays were very similar to those of the 
microarray results and, thus, further confirmed the data (Table 3). 
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Table 3. Analysis technique validation: 7th POD vs. intact skin comparison 
 
Regulation: UP Fold-change 
Gene PCR Affymetrix Illumina 
MMP1  535 594 2690 
CXCL1  58 25 79 
SERPINE1  47 24 39 
IL6  21 8 216 
CXCL2  18 16 68 
IL1B  17 12 318 
CXCL5  10 14 165 
WISP1  7 2 42 
ITGB6  7 2 6 
MMP9  5 10 18 
Regulation: DOWN Fold-change   
Gene PCR Affymetrix Illumina 
ITGA2  4 2 2 
FGF2  4 2 2 
EGF  3 2 3 
FGF10  3 1 1 
MAPK1  2 1 14 
IL6ST  2 2 68 
TGFBR3  3 3 2 
CSF3  2 2 3 
CDH1 2 - 1 
MAPK3 2 1 1 
 
 
5.2 In vivo transplantation of primary skin cells inside the collagen gel 
 
 
The use of the rhCol-III gel for transplantation of autologous keratinocytes and 
fibroblasts was evaluated in porcine full-thickness wounds. Five days after the 
transplantation, the wounds were removed for histological analysis. The formation of 
granulation tissue, as well as the amounts of keratinocytes and collagen, were 
determined. 
  
5.2.1 Cell viability inside the gel 
Cell viability inside the rhCol-III gel was confirmed with a confocal microscope. 
After an overnight incubation, the gel containing the dyed cells was photographed 
under the microscope. The observation proved that both keratinocytes and fibroblasts 
remained viable before transplantation. 
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5.2.2 Full-thickness wound healing 
The formation of granulation tissue was evaluated from the H&E-stained wound 
sections of each wound. The thickness of the granulation tissue was 0.08 ± 0.03 pixels 
(px) in the rhCol-III, 0.08 ± 0.03 px in the keratinocyte, 0.08 ± 0.03 px in the 
fibroblast-keratinocyte groups and 0.06 ± 0.02 px in the untreated group. Thus, the 
results indicate that all treatments increased granulation tissue formation compared 
with the controls. No significant differences were observed between the treatment 
groups. Nevertheless, the analysis suggest that the rhCol-III gel improved granulation 
tissue formation, but the addition of cells showed no effects, at least not during this 5-
day follow-up. 
 
The number of keratinocytes in the wound bed was measured as another marker for 
wound healing. The keratinocytes were identified by immunohistochemical 
pancytokeratin staining of sections of each wound. The pancytokeratin-positive area 
was 0.76% ± 0.17% of the wound area in the rhCol-III, 1.39% ± 0.20% in the 
keratinocyte, 1.02% ± 0.13% in the fibroblast-keratinocyte and 0.83% ± 0.13% in the 
untreated groups. The results suggest that the autologous cultured keratinocytes 
transplanted inside the rhCol-III gel were present in the wound 5 days after 
transplantation. The difference between cell treatment groups was evidenced by less 
pancytokeratin positivity, although the difference between groups did not attain 
statistical significance. Significant differences in the amount of pancytokeratin-
positive cells in the wound were found only in the keratinocyte group between both 
the rhCol-III gel and the empty wound. 
 
For determining the amount of collagen in the wound, the sections were stained with 
Sirius Red and photographed with a polarized light microscope. The images showed 
that the amount of collagen was most increased in wounds treated with rhCol-III gel 
or rhCol-III gel containing only keratinocytes. The number of Sirius Red-positive 
collagen fibrils was 22.0% ± 1.7% per wound area in the rhCol-III, 26.4% ± 2.1% in 
the keratinocyte, 11.0% ± 2.0% in the fibroblast-keratinocyte and 10.3% ± 0.9% in the 
untreated group. Thus, the measurements show that changing the cell-type 
composition of the rhCol-III gel from keratinocytes only to a 50/50 fibroblast-
keratinocyte mixture dramatically altered the amount of collagen detectable by Sirius 
Red staining in the wounds.  
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In conclusion, the results indicate that there are cell-type-dependent differences in the 
stability of rhCol-III in vivo. The fibroblast-containing gel was effectively removed 
from the wound, whereas gels without cells or with keratinocytes only remained 
intact. The results demonstrate that the properties of the rhCol-III gel for skin cell 
transplantation can be significantly altered in a cell-type-dependent manner.  
  
 
6. Discussion 
 
6.1 Donor site wound-healing studies 
 
So far only a limited amount of data are available on what happens in terms of gene 
expression in the wound during various stages of cutaneous wound healing. Most of 
the molecular-level wound-healing data have been obtained from various animal 
models. Several studies have clarified the role of specific genes in various wound 
models in animals. Lees et al. (2013) studied the expression of a tropomyosin isoform 
in a mouse model and showed more rapid wound healing when the gene was deleted. 
In another mouse model, Sun et al. (2013) concluded that IL19 is important for 
cutaneous wound healing because it up-regulates KGF expression. Additionally, in 
vitro gene expression studies have been performed with various cell cultures (Kolář et 
al., 2012). The role of GFs and cytokines especially has been the subject of intense 
focus (Kiwanuka et al., 2012; Lin et al., 2005). 
 
Few results are available on gene expression in human wound healing. Some of these 
reports are based on samples that were collected for another purpose or alternatively 
obtained from nonstandardized wounds (Deonarine et al., 2007, Smiley et al., 2005). 
A comprehensive look at normal wound healing over time has been lacking.  
 
To execute a prospective, molecular-level wound-healing study in the clinic is not 
without problems. One of the biggest challenges in clinical wound-healing research is 
the lack of appropriate controls. To overcome this issue, STSG harvesting of donor 
site wounds was used for this study. Donor site wounds provide an excellent model 
for studying the mechanisms of wound healing in the clinic, since being surgically 
made, they are always standard in depth and size. They are noninfected and clean, and 
moreover these wounds tend to heal very well, which enables the observation of 
normal skin wound healing over time (Orgill, 2009).  
 
To find novel genes associated with wound healing and to map gene profiles of 
thousands of genes, gene expression microarrays were considered as the best option. 
They enable the entire genome to be addressed and require only a small amount of 
tissue (Villaseñor-Park & Ortega-Loayza, 2013). The fact that a 3-mm punch biopsy 
is sufficient to clarify the entire genome was the determining factor in making this 
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study happen. As a method, the microarray is relatively expensive, which limited the 
amount of samples processed in these studies. On the other hand, it is more affordable 
than next-generation sequencing. Another technique for studying gene expression is 
the PCR (Bartlett & Stirling, 2003), which is even more sensitive than the microarray. 
It is however very much limited in the number of genes it can detect and offers few 
opportunities to find new gene associations.  
 
The microarray technique has been in use for more than 20 years (Chang, 1983) and 
the data it produces have been considered reliable. Nevertheless, to confirm the 
reliability of the data, selected samples were processed with two different microarray 
platforms (Affymetrix, Illumina) and single-gene expressions were compared with 
PCR. The microarray results were more than 95% similar and the PCR of the selected 
genes strengthened the credibility of the results even further (Table 3). Barnes et al. 
(2005) made very similar findings in a study comparing the Affymetrix and Illumina 
platforms and showed that these platforms yield highly similar data.  Interestingly, 
Affymetrix and Illumina are technically very different. They differ in oligonucleotide 
physical attachment, probe selection and in design procedure. The Affymetrix arrays 
are produced by in situ synthesis of 25-mer oligonucleotides, while in Illumina 
process the oligonucleotides are attached to microbeads that are then introduced into 
microarrays, using a random self-assembly mechanism (Lockhart et al., 1996). The 
Affymetrix uses multiple probes for each gene together with single-base mismatch 
probes intended as controls for non-specific hybridization. The Illumina system 
produces about 30 copies of the same oligonucleotide on the array, which provides an 
internal technical replication that Affymetrix lacks. Finally, multiple Illumina arrays 
are placed on the same physical substrate, meaning that hybridization and other steps 
are performed in a parallel manner, while the Affymetrix arrays are processed 
separately (Gundersson et al., 2004). An important matter considering the microarray 
platforms is the price. The Illumina is more cost-effective than the Affymetrix. Thus, 
its Human HT12 is the most affordable human array on the market. Affymetrix 
human arrays are roughly twice the Illumina prices (www.helsinki.fi/fugu). 
 In all, 49 biopsies from 18 patients and from six different time points were used for 
these studies. However, more samples were collected, but not all met the quality 
requirements for the microarray process. The RNA integrity number (RIN) (Webster, 
2006) was used as the main determinant for samples suitability for the microarray. To 
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obtain enough good-quality RNA from the acute wound samples was very 
challenging. Success with these samples was random, although they were collected in 
a similar manner by the same surgeons and processed by the same researcher. Thus, 
the entire epidermis with only minor involvement of the dermis was harvested. This is 
crucial, because when the various time points are compared with intact healthy skin, a 
negative fold-change in a gene can result from removal of the cells expressing it, 
while a positive fold-change of another gene can be due to enrichment of cells 
expressing that gene in the remaining dermis.  
 
In our model, the wounds were very standardized (size and depth always the same) 
and were made with an air-driven dermatome machine and, more importantly located 
in the same part of the body (anterior thigh), in all patients. Thus, the skin was similar 
in thickness among patients. The sample collection was performed with identical 3 
mm biopsy punches and always obtained from the middle of the wound. The repeated 
3-mm biopsies healed well and caused only inconspicuous scars, well accepted by the 
patient. 
 
Our data revealed, as expected, the involvement of thousands of genes during the first 
3 weeks of donor site healing. More importantly, the data showed which genes were 
most dominant and additionally revealed that specific groups of genes are more 
important than others. One of these gene groups was the AMPs, which are known to 
play important roles in skin immune defence. Our data revealed that many of them 
also increase highly at different stages of wound repair. PI3, also known as skin 
derived antileukoproteinase (SKALP) or elafin (Wiedow et al., 1990) various S100 
calcium-binding proteins (Zimmer et al., 1995) and defensin beta 4A (DEFB4) (Gallo 
& Hooper, 2012) were among the genes most induced at all our time points. PI3 was 
first found in psoriatic skin, and its expression in healthy human epidermis is low (van 
Bergen et al., 1996). It inhibits serine proteases and influences on cellular 
proliferation, inflammation and infections (Shaw & Wiedow, 2011). Our data 
identified this possible regulatory function of PI3, and we can now closely link this 
gene with all phases of cutaneous wound healing. The S100A genes are known to be 
involved in the regulation of many cellular processes, such as the cell cycle and 
differentiation (Eckert et al., 2004), suggesting possible regulatory functions in wound 
healing. 
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Epidermal differentiation and development of the protective barrier were very evident 
in our data. Many CE-encoding gene expressions were altered during the study period 
follow-up. In addition to the PI3 and S100A already mentioned, these genes included 
SPRR3, LCE3, LOR and FLG. The CE is an insoluble epidermal protective barrier 
that is composed of terminally differentiating stratified squamous epithelial cells, 
which functions together with the lipid envelope as the first line of defence in skin. 
The composition, shape and thickness of the CE vary according to the tissue and its 
state of maturation (Kalinin et al., 2002; Kypriotou et al., 2012). Interestingly, the CE-
linked genes that were manifested in our data with altered expression are located in 
the same gene cluster in chromosome 1q21. This cluster is called the epidermal EDC. 
The EDC is comprised of many genes that encode structural and regulatory proteins 
critical for keratinocyte differentiation and development of the SC (Henry et al., 
2012). In addition, the expressional changes in the various KRTs, especially KRT2, 
can be considered as reflecting keratinocyte differentiation and development of new 
CE. KRT2 is expressed largely in the upper spinous layer of the epidermis and has 
been associated with keratinocyte differentiation (Bloor et al., 2003). Our data suggest 
that KRT2 is a good marker gene for healthy intact skin. In the acute phase, when the 
epidermis is removed, KRT2 decreased 430-fold; on the 3rd and 7th PODs it is 
decreased even more: over 700-fold. Then, 14 days after the operation, KRT2 was 
decreased 200-fold and on the 21st POD, when the wound is clearly closed, KRT2 is 
still decreased 50-fold. This shows that the maturation of skin after wounding requires 
longer periods of time than in our study. However, in large burns when donor site skin 
is limited, surgeons may already use the same donor site 3 weeks after the initial 
STSG. 
 
Several GFs (such as EGF, FGF, HGF, PDGF and VEGF) are generally considered to 
be the most crucial factors in the wound-healing process (Behm et al., 2012). Very 
interestingly, mRNA expression of these GFs remained rather static during our 
follow-up. Thus, our data may indicate that superficial wounding does not alter the 
expression of these genes, in other words these genes are not regulated on a 
transcriptional level in epidermal wound healing, or that the microarray technique is 
not sensitive or specific enough to detect the various forms, modifications, and sizes 
of each GF mRNA. A future alternative to further investigate the regulation of GF 
expression in this clinical wound-healing model would be to utilize sensitive RNA-
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sequencing techniques (Maher et al., 2009; Mutz et al., 2013). Further information 
could be provided by various approaches including epigenetics, proteomics and 
metabolomics (Adamski & Suhre, 2013; Brinton et al., 2012; Ballestar & Esteller, 
2008). On the other hand, GF signalling is also dependent on the corresponding 
receptors on target cells (Alberts et al., 2002). Many GFs are produced by fibroblasts 
that reside in the dermis and wounds in these studies have been superficial. Thus, 
wound depth can affect GF expression. GFs may also be constantly present in skin 
and may accumulate in the ECM. 
 
In conclusion, the data obtained from these studies offer the first large-scale 
perception into the molecular details of normal, superficial, human, skin wound 
healing over time. Moreover, the data enable the researcher to follow any gene’s 
behaviour during the first 3 weeks of the healing process. It is important to understand 
the aetiology of normal healing in detail to better understand chronic and other 
difficult-to-treat wounds. The generated gene library of normal skin wound healing 
can be utilized as an objective tool when observing the effects of various therapies. 
Now that the background data are available the number of controls can be minimized, 
which saves money and time.  
 
A good example of utilization of these data was our study that focused on clarifying 
how NPWT affects gene expression during wound healing. Although NPWT had 
been in routine use for years and was recognized as effective, the molecular 
mechanisms behind this therapy were unknown (Gregor et al., 2008). In comparing 
the data of NPWT patients with nontreated patients, we concluded that NPWT 
enhances the specific inflammatory gene expression associated with granulation, 
epithelial migration and wound healing. Interestingly the data also revealed that 
NPWT’s continued use inhibits epithelial differentiation. 
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6.2 Full-thickness wound healing study 
 
TE provides an array of new approaches for the treatment of deep dermal wounds. 
Hence, cell therapies and novel biomaterials either alone or combined are believed to 
be the answer for problems associated with chronic wound healing (Wong & Gurtner, 
2012).  
 
In the skin, collagen provides cellular support and plays an important role in affecting 
cell attachment, migration, proliferation, differentiation, and survival. It is also an 
important factor in the wound-healing process (Li et al., 2007). Thus, several types of 
collagen products have been popular in various TE applications, such as skin, 
cartilage, cornea and bone TE (Cen et al., 2008; Ferreira et al., 2012; Glowacki & 
Mizuno, 2008). Recombinant collagens, especially have been considered to show 
potential, due to their biocompatibility and safety (Yang et al., 2004). Recombinant 
processes allow the manufacture of human collagens that are pure and free of animal 
components. In addition, these techniques enable the production of all types of 
collagens, including types that exist only superficially in natural tissue. The most 
cost-effective and scalable process for manufacturing recombinant collagens is to use 
genetically engineered microorganisms, such as bacteria (e.g E. coli) and yeasts (e.g 
Pichia pastoris) (Báez et al., 2005; Ramshaw et al., 2009).  
 
To study novel biomaterials in animal models is crucial before they can be adopted 
for clinical use. Only animal models enable the systematic research on the effects of 
the material in living tissue. Additionally, tissue samples at the end of the study can 
be collected for many more detailed analyses, including histology and RNA-based 
experiments. The porcine model was chosen due to similarities between porcine and 
human skin (Montagna & Yun, 1964). In addition, pigs were considered better than 
rodents, due to their larger size. In addition, we had experience with pigs from our 
previous studies. The problem with pigs is that they grow very rapidly and even full-
thickness wounds tend to heal rather quickly. 
 
We made full-thickness wounds on the backs of pigs to investigate the suitability of 
rhColl-III for use as a dermal filler as well as for a vehicle in which to transplant cells. 
Our approach was to prepare collagen-containing syringes with and without cells. The 
cells were centrifuged inside the collagen and incubated in the syringe overnight. The 
syringes proved very handy and could potentially be used as an off-the-shelf product 
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for clinicians. The cells remained viable inside the collagen and it was very 
convenient to apply the material from the syringe.  
 
The results of our study support the use of rhCol-III gel as a favourable material for 
cell delivery in the treatment of full-thickness wounds. Moreover, its kinetics in the 
wound can be altered in a carrier cell-type-dependent manner and are more sustained 
when combined with autologous keratinocytes than with fibroblasts. However, these 
results are preliminary and further studies with longer follow-up times and with larger 
numbers of animals and wounds would be needed to truly ensure the potential of 
rhCol-III in TE of full-thickness wounds. 
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7. Summary and conclusions 
 
The purpose of my PhD project was to study human skin regeneration and to develop 
means for enhancing compromised wound healing, especially in the treatment of 
burns. The first three studies focused on investigating and clarifying the gene 
expression transcriptome in donor site wounds before and after skin graft harvesting 
and during the healing process. The fourth study focused on full-thickness wound 
healing in a porcine model. 
 
The main take-home messages of these studies were: 
 
I   we were able to validate a protocol for following transcriptome changes in the 
clinical setting. The data show that thousands of genes are associated with 
superficial human skin wound healing over time and up to 900-fold changes in 
gene expression during donor site wound healing.  
 
II The effect of NPWT is clearly detectable in the gene profile of treated 
wounds. In the early phases of wound healing, NPWT enhances the expression 
of genes associated with inflammation, epithelial migration and wound 
healing. On the other hand, its continued use may inhibit epithelial 
differentiation. 
 
III In the new-tissue formation phase of wound healing, the expression of several 
thousand of genes differs from that of intact skin. KRT- and CE-encoding 
genes are decreased the most, whereas AMPs, MMPs and collagens are the 
most increased. 
 
IV The rhCol-III gel is suitable as a delivery vehicle for primary skin cells. In 
addition, the gel improves full-thickness wound healing by promoting early 
granulation tissue formation. 
 
Taken together, new features of the epidermal wound-healing trajectory were 
identified (I-III), while other aspects in epidermal regeneration may not be as evident 
as previously believed. Moreover, it enables an objective evaluation of the effects of 
wound-healing therapies. We also showed that (IV) the use of rhCol-III gel as a cell 
therapy vehicle for cultured autologous keratinocytes and fibroblasts in an 
experimental full-thickness wound model were effective.  
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